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The tachykinins, exemplified by substance P, are one of the most intensively studied
neuropeptide families. They comprise a series of structurally related peptides that derive
from alternate processing of three Tac genes and are expressed throughout the nervous and immune
systems. Tachykinins interact with three neurokinin G protein-coupled receptors. The signaling, traf-
ficking, and regulation of neurokinin receptors have also been topics of intense study. Tachykinins
participate in important physiological processes in the nervous, immune, gastrointestinal, respiratory,
urogenital, and dermal systems, including inflammation, nociception, smooth muscle contractility,
epithelial secretion, and proliferation. They contribute to multiple diseases processes, including acute
and chronic inflammation and pain, fibrosis, affective and addictive disorders, functional disorders of
the intestine and urinary bladder, infection, and cancer. Neurokinin receptor antagonists are selective,
potent, and show efficacy in models of disease. In clinical trials there is a singular success: neurokinin
1 receptor antagonists to treat nausea and vomiting. New information about the involvement of
tachykinins in infection, fibrosis, and pruritus justifies further trials. A deeper understanding of disease
mechanisms is required for the development of more predictive experimental models, and for the
design and interpretation of clinical trials. Knowledge of neurokinin receptor structure, and the devel-
opment of targeting strategies to disrupt disease-relevant subcellular signaling of neurokinin receptors,
may refine the next generation of neurokinin receptor antagonists.
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I. INTRODUCTION
Substance P (SP), the first member of the tachykinin family of
peptides, has been called a “pioneering neuropeptide,” since
knowledge gained from studies of tachykinins has informed
our understanding ofmany neuropeptides. Indeed, the discov-
ery of SP as an activity in extracts of horse brain and intestine
with effects on intestinal contractility and blood pressure
marked the identification of the first of many “brain-gut neu-
ropeptides,” which are present in enteric neurons and en-
teroendocrine cells as well as in neurons of the brain (341). SP
belongs to a large family of structurally related peptides, the
tachykinins, that derive from alternative processing of three
Tac genes. The tachykinins interact with three neurokinin re-
ceptors (NKRs) encoded by three Tacr genes. Knowledge of
the structure, function, signaling, and trafficking of these re-
ceptors has guided studies of other GPCRs and, in this sense,
the NKRs may be considered “pioneering receptors.”
The tachykinins are expressed throughout the nervous and
immune systems, regulate an extraordinarily diverse range of
physiological processes, and have been implicated in impor-
tant pathological conditions. The realization that tachykinins
mediate pathological processes that underlie important hu-
man disorders spurred enormous efforts by the pharmaceuti-
cal industry to develop NKR antagonists. These efforts have
been highly successful. There are multiple NKR antagonists,
with varying degrees of selectivity. Many antagonists are ef-
fective in preclinical studies of disease in experimental animals.
Some have progressed to clinical trials, where the results have
been generally disappointing. At present, there is but a single
success: the approval ofNK1R antagonists to treat nausea and
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vomiting after chemotherapy or surgery. However, there are
many plausible explanations for these failures, including an
inadequate understanding of disease mechanisms, the poor
predictive value of animal models, and the inherent redun-
dancy of the tachykinin system. Moreover, new information
about the participation of tachykinins in disease processes,
and a deeper understanding of the NKRs, has served to main-
tain interest in this field, and multiple clinical trials are still in
progress.
In this review, we discuss the contributions of tachykinins
and NKRs to pathophysiological control. We summarize
the discovery, structure, and function of tachykinins and
their receptors, review their roles in major organ systems
(gastrointestinal, respiratory, urogenital, dermal, nervous,
immune) and pathological processes (inflammation, pain,
cancer), and discuss the successes and failures of NKR an-
tagonists in clinical trials. Throughout, we highlight the
challenges of defining functions of tachykinins in health and
disease and identify key gaps in our understanding of this
system.However, the tachykinin literature is vast, and some
aspects are not discussed, including the development of an-
tagonists and an in-depth discussion of tachykinins in the
central nervous system (reviewed in Ref. 127).
II. TACHYKININ PEPTIDES AND GENES
A. Overview
The tachykinins are named for their ability to rapidly stim-
ulate contraction of intestinal muscle, in contrast to the
slower acting bradykinins. They possess a conserved
COOH-terminal sequence (-Phe-X-Gly-Leu-Met-NH2, X
hydrophobic), which is required for receptor activation.
The major mammalian tachykinins are SP, neurokinin A
(NKA), and neurokinin B (NKB), together with NH2-termi-
nally extended forms of NKA, including neuropeptide K
(NPK) and neuropeptide  (NP) (FIGURE 1). SP, NKA,
NKB, and NPK were discovered as biological activities in
tissue extracts and were subsequently identified by isola-
tion, sequence, synthesis, and analysis of the Tac genes.
Other tachykinins were first identified in the Tac genes, and
were subsequently purified from tissues. These include
NP, hemokinin-1 (HK-1) and the NH2-terminally extended
forms ofHK-1, endokininA (EKA), andEKB (FIGURE 1). Three
genes encode the tachykinins: Tac1 (pre-pro-tachykinin-A,
Ppt-a), Tac3 (Ppt-b), and Tac4 (Ppt-c) (FIGURE 2). Tac1
encodes SP, NKA, NPK, andNP; Tac3 encodes only NKB;
and Tac4 encodes HK-1 and EKA, EKB, EKC, and EKD.
Although Tac2 was initially assigned to the gene encoding
the NKA precursor, it was subsequently found to be iden-
tical to Tac1.
B. Tac1-Derived Tachykinins
1. SP
In the course of investigating the tissue distribution of ace-
tylcholine, von Euler and Gaddum (341) reported the dis-
covery of an activity in extracts of horse intestine and brain
that induced atropine-resistant contraction of isolated rab-
bit jejunum and fall in blood pressure of anesthetized rab-
bits (FIGURE 3A). Extraction of tissues with acid and alcohol
allowed the preparation of a water-soluble powder that
retained high activity and was called “preparation P” and
later “substance P.” Activity was highest in intestinal mus-
cle, which contains enteric nerves, and in the brain, suggest-
ing a neuronal origin. Incubation of extracts with trypsin
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FIGURE 1. The amino acid sequences of the tachy-
kinins and tachykinin gene-related peptides. Note the
presence of the signature tachykinin sequence X-Phe-
X-Gly-Leu-Met-NH2 (red) in all of the tachykinins. This
sequence is lacking in EKC and EKD, which are not
tachykinins although they derive from the Tac4 gene.
HK-1 peptides are unique since they differ between
mammalian species, whereas other tachykinins are
conserved. The existence of an NH2-terminal Arg res-
idue of rat/mouse HK-1 is debatable.
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destroyed biological activity, leading von Euler to conclude
that “the active principal is of protein nature.”
Thirty years after its discovery, SP was identified as peptide
from an unrelated line of investigation. While purifying
corticotrophin-releasing factor from bovine hypothalamus,
Leeman (180) identified fractions that stimulated atropine-
resistant salivation in rats. This activity, named sialogen,
was destroyed by proteases and had an estimated mass of
8,000–10,000 Da. Shortly thereafter, Lembeck (181) re-
ported that preparations of SP also stimulated salivary se-
cretion and suggested that sialogen and SP were the same.
Starting with 20 kg of bovine hypothalami, Chang and
Leeman isolated 0.15 mg of pure SP and determined its
amino acid composition (FIGURE 3B) (60) and sequence
(61), enabling synthesis of SP with the expected biological
activity (337).
2. NKA
NKA (substance K, neurokinin , neuromedin L), which is
highly homologous to SP, was identified as an activity in
extracts of porcine spinal cord that stimulated contraction
of guinea pig ileum (151) (FIGURE 1). The existence of NKA
was predicted from the Tac1 gene structure (233).
3. NPK
NPK, a 36-amino acid peptide with the COOH-terminal
sequence of NKA (FIGURE 1), was isolated from the porcine
brain using methods for detecting COOH-terminal amides
of bioactive peptides (332). NPK stimulated gall bladder
contraction, plasma extravasation, hypotension, and bron-
chial smooth muscle spasm. The existence of NPK was pre-
dicted from the Tac1 gene (233).
4. NP
NP, a 21-amino acid peptide, was predicted from the rat
Tac1 gene (168) (FIGURE 1). NPwas subsequently isolated
from the rabbit intestine (142). Like NPK, NP is an NH2-
terminally extended form of NKA, but NP lacks residues
3–17 of NPK (FIGURE 1).
76
hTac1
αTac1 1 2 3 4 5
6
SP
7 δTac1 1 2 3 4
SP
7
βTac1 1 2 3 4 5 65
65
SP
7 γTac1 1 2 3
SPNKA NKA
NPK Npγ
7
hTac4
αTac4 1
1 3
3 4 5
4 5
2 1 5
5
2
1 2
HK-1
EKA
EKC
δTac4
EKB
βTac4 2
EKB
γTac4
EKBEKD
hTac3
αTac3 5a 61 2 3 4 5
NKB
7 βTac1 1 2 3 4
NKB
7
7654321
5 5a4321
54321
FIGURE 2. Structures of the human (h) Tac genes and the existence of mRNA splice variants. The peptide
products are indicated by the horizontal black bars beneath the mRNA structures. [Adapted from Shimizu et
al. (305).]
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5. Tac1
Two splice variants of Tac1 (Tac1, Tac1) were first
cloned from bovine striatum (233) (FIGURE 2). Both
mRNAs encoded SP. The COOH terminus of SP was followed
by Gly, which donates the amide group of the COOH-
terminal Met, and Gly was followed by a dibasic Lys-Arg
processing site. An Arg-Arg sequence formed the NH2-ter-
minal processing site. Whereas Tac1 encoded SP alone,
Tac1 encoded an additional peptide with the tachykinin
signature sequence (-Phe-X-Gly-Leu-Met-NH2) and appro-
priate residues for processing. The peptide was named sub-
stance K (NKA) due to homology with amphibian kassinin.
Tac1 has been cloned from several species, which confirmed
existence of Tac1 and Tac1, and identified the Tac1 and
Tac1 splice variants (51, 168). These splice variants lack var-
ious exons; encode a combination of SP,NKA,NPK, andNP
(FIGURE 2); and are differentially expressed in various tissues.
C. Tac3-Derived Tachykinins
1. NKB
NKB (neurokinin , neuromedin K), which resembles SP and
NKA, was isolated from porcine spinal cord as an activity that
stimulates contraction of the guinea pig ileum (143) (FIGURE 1).
2. Tac3
Tac3was first identified in the bovine as a gene that encoded
neuromedin K (NKB) (164). There are two forms of Tac3,
both of which encode a single tachykinin, NKB (FIGURE 2).
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FIGURE 3. Landmark events in the history of tachykinins and neurokinin receptors. A: the discovery of substance
P (SP). The kymograph tracings show contractions of the rabbit jejunum in response to acetylcholine (a.c.) (A, C)
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D. Tac4-Derived Tachykinins
1. HK and EK
The HKs and EKs were discovered by analysis of the Tac4
gene rather than by extraction and bioassays of tissue ex-
tracts (FIGURE 1) (248, 362).
2. Tac4
The appreciation that tachykinins control the myeloid lin-
eage and regulate lymphoid differentiation led to the search
for tachykinins in the hematopoietic system (362). A cDNA
was identified that encoded an open reading frame of 128
amino acids, including a stretch of 11 amino acids with
tachykinin signature sequence flanked by dibasic processing
sites and with a Gly adjacent to the COOH-terminal Met.
The gene was designated Ppt-c (Tac4), and the peptide
named HK-1 to reflect its presence in hematopoietic cells
(FIGURE 1). Although mouse and rat Tac4 are homologous,
the human precursor is truncated to 68 amino acids, and
human HK-1 differs from the mouse/rat form within the
NH2-terminal region. Thus HK-1 differs from the other
tachykinins, which are conserved across mammals. More-
over, the human precursor contains two monobasic cleav-
age sites and has the potential to generate truncated HK-
1(4–11) as well as full-length HK-1. Four splice variants of
human Tac4 have been identified (, , , ), which are
generated from a combination of five exons (FIGURE 2)
(248). These splice variants are capable of encoding other
peptides, named endokinins in view of their proposed role
in endocrine tissues. EKA and EKB are NH2-terminally ex-
tended forms of HK-1 and are true tachykinins. As ex-
pected, HK-1, EKA, and EKB have SP-like biological ac-
tions and can interact with NKRs (248, 362). EKC and
EKD lack the tachykinin sequence, have minimal tachy-
kinin-like actions, and show negligible affinity for the
NKRs. They are tachykinin gene-related peptides, not
tachykinins.
III. NEUROKININ RECEPTORS AND GENES
A. Overview
The first suggestion of multiple receptors for tachykinins
came from comparisons of the potencies of mammalian and
nonmammalian tachykinins in bioassays. Cloning of three
NKRs (NK1R, Tacr1; NK2R, Tacr2; NK3R, Tacr3) con-
firmed this proposal, representing a major advance in this
field. The Tacr genes possess five exons and four introns,
which interrupt the protein coding sequences. They encode
GPCRs with seven membrane-spanning domains, three ex-
tracellular and intracellular loops, and extracellular NH2
and intracellular COOH termini. The availability of the
cloned receptors enabled studies of receptor structure, func-
tion, and regulation and facilitated the identification of se-
lective antagonists. However, there is still much to learn
about this family of receptors, especially the NK2R and
NK3R, which have been less thoroughly studied. Impor-
tantly, to our knowledge, the crystal structures of the NKRs
have not been reported, which would provide key informa-
tion about receptor activation and signaling.
B. NKR Structure
1. NK1R
The NK1R (SP receptor) was cloned from a rat brain cDNA
library by electrophysiological assessment of receptor ex-
pression inXenopus oocytes and cross-hybridization to bo-
vine NK2R (substance K receptor) (355), which had been
cloned earlier (203). A clone of 3,408 nucleotides was iden-
tified encoding a GPCR of 407 residues (FIGURES 3C AND
4A). When expressed in monkey kidney COS cells, the clone
conferred high-affinity binding for SP, that was displaced by
SP, NKA, and NKB (IC50 SP  NKA  NKB). Although
there is a high degree of similarity of NK1Rs between dif-
ferent species (94.5% identity between rat and human),
differences at key residues can affect interaction with antag-
onists.
A splice variant of the human and guinea pig NK1R miss-
ing exon five encodes a COOH-terminally truncated
NK1R of 311 residues that lacks most of the intracellular
C-tail (FIGURE 4B) (19, 98). The truncated human receptor
has been detected in monocytes and macrophages (173),
discrete brain regions (cortex, cerebellum) (172), and co-
lonic epithelial cells of patients with colitis-associated can-
cer, where the short form is preferentially upregulated
(108). Since the truncated receptor signals differently from
the full-lengthNK1R (see sect. IIIC), this differential expres-
sion is of probable functional importance.
2. NK2R
The NK2R (substance K receptor) was the first tachykinin
receptor to be cloned. Nakanishi’s group used the new ap-
proach of expression cloning, in which mRNAs from a
bovine stomach cDNA library were expressed in Xenopus
oocytes (203). From 3  105 clones, a single clone was
identified that conferred an electrophysiological response to
NKA. The 2,458-nucleotide sequence encoded a GPCR of
384 residues. Oocytes expressing this clone responded to
tachykinins with a potency ranking of NKANKBSP.
3. NK3R
The NK3R (NMB receptor) cDNA was cloned from rat
brain by hybridization with bovine NK2R cDNA, and pre-
dicted to encode a GPCR of 452 residues (304). When ex-
pressed in Xenopus oocytes, the clone conferred electrophys-
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iological responses to tachykinins, and ligand-binding experi-
ments on membranes from NK3R-expressing COS cells
revealed the rank order of potency of NKBNKA SP.
C. NKR Signaling
Although NKR signaling has been thoroughly studied,
many aspects warrant further attention. First, NKR signal-
ing has been studied mostly in cell lines rather than primary
cells, where the intricacies of signaling depend on the level
of NKR expression, the compliment of signaling proteins,
and the cellular environment. Second, most information
derives from studies of high-affinity ligands (SP for NK1R).
Since agonists can stabilize distinct GPCR conformations
that transmit unique signals (biased agonism, reviewed in
Ref. 281), individual tachykinins may signal differently via
the same NKR, with diverse outcomes. Third, NKR sig-
naling is usually studied by measuring total cellular levels
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FIGURE 4. Comparison of regulation and sig-
naling of the full-length and truncated human
NK1R. A: the full-length NK1R is phosphorylated
by GRKs and PKC within the COOH terminus and
interacts with -arrestins, which mediate desen-
sitization, endocytosis, and endosomal signal-
ing (75). The receptor activates Ca2, ERK1/2,
NF-B, and PKC- and stimulates IL-8 secretion
(175). B: the truncated NK1R lacks most of the
COOH terminus, is not phosphorylated, and does
not interact with -arrestins. As a result, it is
defective in desensitization and endocytosis and
does not assemble -arrestin signalosomes (75,
183). The truncated receptor does not couple
robustly to Ca2 and NF-B and inhibits PKC
phosphorylation and IL-8 secretion (175).
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of second messengers, rather than second messenger gen-
eration in subcellular compartments. Compartmental-
ized signaling can also lead to divergent outcomes, which
explains how GPCRs that couple to the same G proteins
can transduce specific signals (223). Finally, most studies
have examined signaling by full-length unmodified recep-
tors. Variants of the same receptor, which can be gener-
ated by alternative splicing or by posttranslational mech-
anisms, can signal by distinctly different mechanisms.
This differential signaling may be important in patho-
physiological situations where alternative receptor pro-
cessing can occur.
1. Initiation of NKR signaling
The major proximal pathways that are activated by
tachykinins in NKR-transfected Chinese hamster ovary
(CHO) and rat kidney epithelial (KNRK) cells include the
following: 1) activation of phospholipase C, leading to
formation of inositol triphosphate, which mobilizes in-
tracellular stores of Ca2, and diacylglycerol, which ac-
tivates protein kinase C (PKC); 2) activation of adenylate
cyclase, resulting in accumulation of cAMP and stimula-
tion of protein kinase A (PKA); and 3) activation of phos-
pholipase A2 and generation of arachidonic acid, a pre-
cursor of lipid inflammatory mediators (FIGURE 5). SP-
induced activation of the NK1R in human embryonic
kidney (HEK293) cells also causes a rapid change in mor-
phology, including the formation of blebs in the plasma
membrane, which involves the Rho-associated ROCK
system and phosphorylation of the myosin regulatory
light chain (212). SP-evoked blebbing is not related to
apoptosis, which often accompanies blebbing, but rather
to formation of microparticles, a mechanism of intercel-
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FIGURE 5. Mechanisms of neurokinin receptor signaling from the plasma membrane. 1: SP activation of the
NK1R at the plasma membrane initiates G protein-mediated signaling events that include activation of phos-
pholipase C (PLC), formation of inositol trisphosphate (IP3) and diacylglycerol (DAG), mobilization of intracellular
stores of Ca2, and activation of PKC; activation of adenylyl cyclase (AC), formation of cAMP, and activation of
PKA; activation of phospholipase A2 (PLA2), formation of arachidonic acid (AA), and generation of PGs,
leukotrienes (LX), and thromboxane A2 (TXA2); and activation of ROCK and phosphorylation of myosin regula-
tory light chain (MLC). 2: the NK1R also transactivates the EGFR by a mechanism that involves G protein-
dependent activation of members of the a disintegrin and metalloproteinase (ADAM) domain-containing
proteases that cleave and liberate membrane-tethered EGFR agonists. The EGFR dimerizes, phosphorylates
(P), and assembles a SHC/Grb2 complex that leads to activation of ERK1/2. There are many interactions
between these pathways, and the precise details of activation vary between cell types. 3: NK1R signaling leads
to diverse and sometimes cell type-specific effects that include inflammation, proliferation, anti-apoptosis,
neuronal excitation, and migration.
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lular communication that has been implicated in dis-
ease (63).
SP signaling has been extensively studied in U373MG hu-
man astrocytoma cells, which express endogenous NK1R,
and in NK1R-transfected NCM460 human colonocytes. In
both cell types, SP and the NK1R transactivate the epider-
mal growth factor receptor (EGFR), which leads to activa-
tion of mitogen-activated protein kinases (MAPK), extra-
cellular signal regulated kinases (ERK) 1 and 2, DNA syn-
thesis, and proliferation (FIGURE 5) (54, 158). This
mechanism partially mediates the ability of the NK1R to
promote healing of the inflamed colonic epithelium (52).
Mucosal healing also depends on the anti-apoptotic effect
of SP, which involves Janus kinase 2 (JAK-2) and phospho-
inositide 3-kinase (PI3K)-mediated activation of the anti-
apoptotic molecule Akt (protein kinase B) (159). SP also
activates Akt in glioblastoma cells (3).
In view of the proinflammatory actions of SP (see sect. IV),
NK1R inflammatory signaling has been extensively studied. In
U373MG cells, SP and the NK1R activate p38 and generate
proinflammatory cytokines, including interleukin (IL)-6 and
IL-8 (79, 94). SP activates the master proinflammatory tran-
scription factor nuclear factor kappa B (NF-B) in NCM460
cells by mechanisms that involve activation of Rho family
kinases and PKC, leading to formation of IL-6, IL-8 and
tumor necrosis factor  (TNF-) (161, 363). SP induces cyclo-
oxygenase-2 expression and prostaglandin (PG) E2 produc-
tion in these cells via PKC- and JAK3/STAT3/5 pathways
(160).
In addition to their role in GPCR desensitization and endo-
cytosis, -arrestins recruit signaling proteins to internalized
GPCRs and mediate sustained signaling from endosomes
(223). In NK1R-transfected KNRK cells and dermal endo-
thelial cells that naturally express the NK1R, SP induces the
assembly of an endosomal signaling complex (signalosome)
comprising NK1R, -arrestin, Src, MEKK, and ERK1/2
(FIGURE 6) (75). This complex promotes the nuclear trans-
location of activated ERK1/2, which is necessary for the
proliferative and anti-apoptotic effects of SP. The truncated
NK1R lacks phosphorylation sites that are necessary for
high-affinity -arrestin interactions, and thus cannot as-
semble the complex (FIGURE 4B). Although protease-acti-
vated receptor-2 (PAR2) also assembles -arrestin-depen-
dent signalosomes, activated ERK1/2 is retained in the cy-
tosol (75). This difference in the subcellular fate of ERK1/2
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FIGURE 6. Compartmentalized signaling of the NK1R from endosomal membranes. 1: -Arrestins (-arrs)
recruit the NK1R, Src, MEKK, and ERK1/2 to endosomes and thereby assemble a signalosome that mediates
ERK1/2 phosphorylation and activation. -Arrestin-activated ERK1/2 translocate to the nucleus. 2: Under
normal circumstances, ERK1/2 mediate the proliferative and anti-apoptotic actions of SP. 3: When ERK1/2
activation is abnormally sustained, as occurs in cells that lack active ECE-1, ERK1/2 phosphorylate and induce
Nur77, which induces cell death.
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depends on the affinities of the NK1R and PAR2 for -ar-
restins, with PAR2 exhibiting a higher affinity and assem-
bling a more stable complex that retains activated ERK1/2
in the cytosol (251).
There are other differences in signaling of the full-length
and truncatedNK1R.Whereas SP stimulates NF-B activity
and IL-8 expression in cells expressing full-lengthNK1R, SP
stimulation of the truncated receptor inhibits IL-8 expres-
sion (FIGURE 4B) (175). These differences may have impli-
cations for tachykinin signaling under pathological condi-
tions where selective upregulation of the truncated receptor
is observed (108).
Posttranslational modifications, including phosphoryla-
tion (see below) and glycosylation, can influence NK1R
signaling. The NK1R has two potential sites for N-linked
glycosylation: Asn-14 and Asn-18. The importance of
glycosylation has been examined by expressing a mutated
human NK1R lacking these sites in NCM460 colonocytes
(331). Mutation prevented NK1R glycosylation, acceler-
ated SP-induced NK1R endocytosis, and suppresses SP-
stimulated IL-8 secretion (331). Thus glycosylation sta-
bilizes the NK1R in the plasma membrane and controls
proinflammatory signaling. Whether NK1R glycosyla-
tion is regulated under pathophysiological conditions is
unknown.
The endogenous NK1R signals differently in primary neu-
rons (190). Nociceptive dorsal root ganglia (DRG) neurons
release SP, which mediates neurogenic inflammation and
pain (see sect. IVF). However, SP can also act in a poorly
understood autocrine fashion to activate the NK1R on
DRG neurons and sensitize transient receptor potential va-
nilloid 1 (TRPV1), leading to hyperalgesia but not sponta-
neous pain. Although SP activates PLC in DRG neurons,
resulting in PKC-mediated sensitization of TRPV1, it does
not robustly elevate intracellular Ca2. Instead, the NK1R
induces a Gi/o-dependent release of reactive oxygen species
(ROS), leading to oxidation and activation of M-type K
channels and consequent neuronal hyperpolarization,
which explains why SP does not cause spontaneous pain.
Importantly, when overexpressed in neurons, the NK1R
induces a robust Ca2 signal and inhibitsM-currents. These
results highlight the importance of understanding signaling
by endogenous receptors in primary cells.
2. Termination of NKR signaling
GPCR signaling is terminated by mechanisms that remove
agonists from the extracellular fluid (reuptake, degradation)
and that restrict the capacity of the receptor to couple to sig-
naling machinery (uncoupling, desensitization) (FIGURE 7).
Neprilysin is a cell-surface metalloendopeptidase that de-
grades SP in the extracellular fluid and thereby terminates
NK1R activation. Neprilysin disruption suppresses SP deg-
radation and causes widespread NK1R-dependent plasma
extravasation (195). Neprilysin-deficient mice are more
susceptible to SP-dependent inflammation of the intestine
(24, 325) and skin (296), which illustrates the importance
of this mechanism of restricting SP signaling.
After stimulation with SP, subsequent responses usually
fade (desensitize) and then recover (resensitize). G protein-
coupled receptor kinases (GRKs) and -arrestins mediate
desensitization of the NK1R (FIGURE 7). GRK2, GRK3, and
GRK5 interact with and can phosphorylate the NK1R (23,
141, 170). The NK1R is extensively phosphorylated, which
promotes high-affinity interactions with -arrestins at the
plasma membrane and in endosomes. -Arrestins sterically
uncouple the NK1R from G proteins and desensitize G pro-
tein-mediated signaling. The truncated NK1R is resistant to
desensitization because it lacks GRK phosphorylation sites
and does not interact with -arrestins (183).
Mechanisms that control NK1R signaling from plasma
membranes (SP degradation, NK1R interaction with -ar-
restins) similarly control NK1R signaling from endosomal
membranes (FIGURE 7). Endothelin-converting enzyme-1
(ECE-1) is a membrane metalloendopeptidase that degrades
SP in endosomes and thereby disassembles the SP/NK1R/
-arrestin/Src signalosome, which attenuates ERK1/2 signal-
ing (68, 259, 285). The importance of this mechanism is illus-
trated by the finding that ECE-1 inhibition causes sustained
SP-induced ERK1/2 activation, leading to activation of the
death receptor Nur77 and neurotoxicity (FIGURE 6) (68).
Resensitization of SP responses requires NK1R endocytosis,
dissociation of -arrestins, and NK1R recycling (see sect.
IIID). However, after stimulation with SP, a substantial
proportion of desensitized NK1Rs remain at the plasma
membrane, where they resensitize by a mechanism that in-
volves recruitment of protein phosphatase 2A, a -arrestin
binding partner that can dephosphorylate and resensitize
the NK1R (FIGURE 7) (224).
D. NKR Trafficking
NK1R endocytosis is widely used to detect sites of SP release
and receptor activation in the nervous system. Although
endocytosis is also a key component of signal transduction
(223, 342), the importance of NK1R trafficking for signal-
ing in the nervous system is not fully understood.
1. Pathways of NKR trafficking
In NK1R-transfected KNRK and HEK293 cells, SP stimu-
lates rapid NK1R endocytosis (FIGURE 7) (103, 110, 210).
However, the fate of the internalized NK1R depends on the
stimulation conditions (286). After brief exposure to low
concentrations of SP, the NK1R traffics to rab5a-positive
endosomes. Endosomal acidification dissociates SP from
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the NK1R, SP is degraded in endosomes by ECE-1, and the
NK1R recycles (259, 285). After sustained incubation with
high SP concentrations, as may occur during inflammation,
the NK1R is ubiquitinated and degraded (67). Brief stimu-
lation with SP evokes NK1R endocytosis and recycling in
myenteric (109, 316) and spinal (202) neurons.
SP also stimulates NK1R trafficking in vivo. In rats, SP
stimulates endocytosis and recycling of the NK1R in endo-
thelial cells of tracheal postcapillary venules, which coin-
cides with desensitization and resensitization of plasma ex-
travasation (41). Stimuli that promote SP release from the
central projections of DRG neurons in the dorsal horn of
the spinal cord, including electrical stimulation of dorsal
roots and intraplantar injection of the TRPV1 agonist cap-
saicin, trigger NK1R endocytosis in neurons in superficial
laminae of the dorsal horn (199, 202). Stroking of the mu-
cosa of the guinea pig ileum evokes NK1R endocytosis in
myenteric neurons, which suggests that stimulation of en-
teric afferent mechanoreceptors promotes SP release and
NK1R activation (317). Intestinal inflammation causes
NK1R endocytosis in myenteric and spinal neurons, which
reflects sustained release of SP from primary spinal afferent
neurons in the inflamed intestine and dorsal horn (198,
361). Thus NK1R endocytosis occurs under pathophysio-
logical conditions associated with SP release. The endocy-
tosed NK1R has been used to deliver toxins, allowing abla-
tion of NK1R-expressing spinal neurons and determination
of their contribution to nociception (200). However, de-
spite the extensive studies of NK1R endocytosis in the ner-
vous system, the functional importance of this trafficking is
unknown.
Like the NK1R, the NK2R internalizes and recycles (102).
However, in neurons of the paraventricular hypothalamic
nucleus, endogenous NKB stimulates internalization and
trafficking of the NK3R to the nucleus (136). Importins
mediate nuclear trafficking of the NK3R, which then asso-
ciates with transcriptionally active chromatin and thereby
controls gene transcription (97, 137).
2. Mechanism and function of NKR trafficking
The NK1R internalizes in cell lines and neurons by a clath-
rin-dependent mechanism that requires dynamin, rab5a,
and -arrestins (FIGURE 7) (109, 110, 210, 259, 294).
Rab5a also mediates NK1R trafficking to endosomes in a
perinuclear location, and rab4a and rab11a mediate NK1R
recycling (286, 294). The NK1R has also been detected in
lipid rafts of HEK293 cells, suggesting the existence of non-
clathrin-dependent trafficking mechanisms (169).
Endocytosis does not mediate NK1R or NK2R desensitiza-
tion (102), which instead depends on -arrestins. However,
NK1R resensitization requires endocytosis, intracellular
processing, and recycling. Thus disruption of the mecha-
nisms of NK1R endocytosis (294) or recycling (286) blocks
the resensitization of SP-induced Ca2 signals. By degrad-
ing SP in endosomes, ECE-1 disassembles the NK1R/-ar-
restin signalosome, which allows the receptor, freed from
-arrestins, to recycle and resensitize (259, 285). By pre-
venting the NK1R resensitization, ECE-1 inhibitors attenu-
ate SP-stimulated plasma extravasation, which illustrates
the importance of NK1R recycling for sustained inflamma-
tory signaling of SP (55).
The NK1R can regulate trafficking and signaling of other
GPCRs by mechanisms that include competition of recep-
tors for -arrestins and physical interactions between recep-
tors. In KNRK cells and enteric neurons, the activated
NK1R sequesters -arrestins in endosomes and thereby im-
pedes -arrestin-dependent endocytosis and desensitization
of the NK3R, which has a low affinity for -arrestins (293).
The activated NK1R similarly blocks agonist-stimulated
trafficking of the -opioid receptor (356). The NK1R and
-opioid receptor can also form heterodimers in HEK293
cells, where NK1R activation promotes -opioid receptor
endocytosis, and delays -opioid receptor resensitization,
presumably by causing its prolonged retention in endo-
somes with -arrestins (261). Whether these complexes as-
semble in primary neurons is unclear. However, studies in
living cells exclude the existence of NK1R homodimers or
oligomers of theNK1R and suggest that NK1Rs concentrate
in microdomains at the plasma membrane (213).
Conversely, other receptors can control NK1R trafficking.
Transforming growth factor- (TGF-) delays SP-stimu-
lated endocytosis of the NK1R in T cells of the inflamed
intestine (30). Although the mechanism of this effect is un-
FIGURE 7. The regulation and NK1R signaling and trafficking. 1: The cell-surface peptidase neprilysin (NEP) degrades and inactivates SP in the
extracellular fluid and thereby limits NK1R activation. 2: The SP-occupied NK1R is a substrate for GRK 2, 3, and 5, which phosphorylate Ser and
Thr residues in intracellular loop 3 and the COOH-terminal tail. Phosphorylation increases affinity of the NK1R for -arrestins (arrs), which
translocate to the plasma membrane, interact with the NK1R, and mediate G protein uncoupling and receptor desensitization. -Arrestins also
recruit protein phosphate 2A (PP2A), which can dephosphorylate and thereby resensitize the cell-surface receptor. 3: -Arrestins are adaptor
proteins for clathrin and AP2 and thereby promote dynamin-dependent endocytosis of the SP and the NK1R. 4: By recruiting the NK1R together
with Src, MEKK, and ERK1/2 to endosomes, -arrestins assemble signalosomes that allow the endocytosed NK1R to continue to signal. Rab5a
mediates trafficking to early endosomes. 5: The NK1R can rapidly recycle from superficially located endosomes by rab4a- and rab11a-dependent
mechanisms. 6: Alternatively, the NK1R traffics to endosomes in a perinuclear location that contain ECE-1. ECE-1 degrades SP in acidified
endosomes and thereby destabilizes the SP/NK1R/-arrestin/Src/MEKK and ERK1/2 signaling complex. 7: The NK1R then slowly recycles,
which also mediate resensitization (8). 9: After sustained stimulation with high concentrations of SP, the NK1R is ubiquitinated and traffics to
lysosomes, where degradation downregulates SP signaling.
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known, it may be relevant to inflammation because TGF-
amplifies SP-induced inflammatory signaling, and the com-
bination of TGF- and SP stimulates release of interferon-
and IL-17 from intestinal inflammatory T cells, whereas
either agonist alone has no effect.
E. NKR Expression
The NKR system is remarkably plastic. Alterations in re-
ceptor expression influence responses to tachykinins and
contribute to pathology, with implications for therapy with
antagonists.
1. NK1R
The NK1R is upregulated in the inflamed organs, including
in the intestine of patients with inflammatory bowel disease
(IBD) (282), in the pancreas of mice with acute pancreatitis
(33), and in mesenteric fat of mice with colitis (144), which
may exacerbate the inflammatory effects of SP. However,
the NK1R is also upregulated in noninflammatory states,
including in spinal neurons of rats during chronic stress (43)
and the cingulate cortex of HIV-positive patients (84).
NF-B is a major regulator of NK1R expression during
inflammation. A putative NF-B binding site was noted in
the promoter of the human NK1R gene (327) and was sub-
sequently confirmed experimentally (307). NF-B mediates
IL-12- and IL-18-induced NK1R transcription in splenic T
cells (347), IL-1-stimulatedNK1R expression in astrocytes
(117), and expression of the truncated NK1R in breast can-
cer cells (275). SP and theNK1R can in turn activate NF-B,
leading to transcription of proinflammatory genes (26,
161).
The NK1R gene promoter contains putative binding sites
for additional transcription factors, including AP-1, Sp1,
and Oct-2, which regulate many inflammatory genes (327).
Leukemia inhibitory factor, a cytokine of the IL-6 family,
promotes NK1R expression in airway epithelial cells by
JAK/STAT and MAPK/ERK pathways (128), and JNK up-
regulates the NK1R in acinar cells during pancreatitis (154).
Notably, SP activates the JAK/STAT pathway in colonic
epithelial cells leading to PGE2 secretion (160).
2. NK2R
The NK2R is upregulated in the ileum of rats with acute
necrotizing enterocolitis (303), and in inflammatory cells in
the colon of patients with IBD (282), whichmay explain the
anti-inflammatory effects of NK2R antagonists. In fibro-
blasts, TGF-1 and IL-1 stimulate NK2R expression,
whereas IL-3 and granulocyte-macrophage colony stimu-
lating factor (GM-CSF) have the opposite effect (21). Two
p53 consensus sequences in the NK2R promoter are critical
for the suppressive effects of NKA on the proliferation of
hematopoietic progenitor cells (340).
3. NK3R
There is a complex pattern of NK3R regulation during in-
flammation. Whereas carrageenan-induced peripheral in-
flammation reduces responsiveness of spinal dorsal horn
neurons to a NK3R agonist (2), intraplantar injection of
Formalin or adjuvant upregulates NK3RmRNA expression
in the spinal dorsal horn (209).
Alterations in the expression of the NK3R and NKB in the
uterus during pregnancy point to important roles in repro-
duction and reproductive disorders. In the rat placenta, nor-
mal late pregnancy is associated with downregulation of
NKB and NK3R (249). However, there are marked in-
creases in the circulating concentrations of NKB in individ-
uals with pre-eclampsia, NKB and NK3R levels in the pla-
centas of women with pre-eclampsia are elevated, and
NK3R expression in umbilical vein endothelial cells is up-
regulated in severe pre-eclampsia (193, 250). These results
point to a major role of NKB and the NK3R in hypertension
and pre-eclampsia, whereNK3R blockade is a possible ther-
apy.
Genetic studies suggest an important role for NKB and the
NK3R in the hypothalamic-pituitary-gonadal axis in hu-
mans. A search for genetic associations that may cause iso-
lated hypogonadotropic hypogonadism identified four ped-
igrees of Turkish descent with severe congenital gonadotro-
pin deficiency and pubertal failure, with all affected subjects
homozygous for loss-of-function mutations in the NKB or
NK3R genes (335). A study of a larger and more ethnically
diverse population revealed that mutations of NKB and
NK3R occur in5% of a normosmic isolated hypogonado-
tropic hypogonadism population (107). Thus NKB and
NK3R may be critical regulators of gonadal function.
IV. PATHOPHYSIOLOGICAL FUNCTIONS OF
TACHYKININS
A. Overview
Although knowledge of the localization of tachykinins and
NKRs and the availability of selective antagonists and mice
lackingTac andTacr genes have contributed enormously to
our understanding, there are formidable challenges to de-
fining the pathophysiological functions of tachykinins. The
observation that exogenous tachykinins exert an effect does
not imply that endogenous tachykinins have the same ac-
tions. Altered tachykinin and NKR expression in disease,
and the inherent redundancy of the tachykinin system, with
multiple peptides and receptors, can complicate interpreta-
tions. There are obvious limitations in extrapolating find-
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ings from inbred rodents under controlled conditions to
diverse human subjects, and experimental animal models
rarely recapitulate human diseases, especially those of un-
known etiology. Despite these caveats, there is a wealth of
information about the pathophysiological functions of
tachykinins. This section discusses the functions of tachy-
kinins in major organs systems (gastrointestinal, respira-
tory, urogenital, dermal, nervous, immune) and in impor-
tant pathological processes (inflammation, pain, cancer).
B. Gastrointestinal Tract
The localization and function of tachykinins in the gastro-
intestinal tract have been reviewed (305). Although tachy-
kinins are found in intestinal immune and enterochromaffin
cells, the major sources in the gut are enteric neurons, fol-
lowed by nerve fibers from dorsal root and vagal ganglia.
Tachykinin-containing fibers surround enteric ganglia,
ramify through muscle, form a perivascular mesh around
submucosal arteries, and supply the mucosa. These fibers
are in close proximity to cells expressing NKRs. The NK1R
is expressed by enteric neurons, interstitial cells of Cajal,
epithelial cells, and lymphocytes and macrophages of the
lamina propria; the NK2R is expressed by myocytes, neu-
ronal varicosities, and epithelial cells; and the NK3R is
mostly neuronal. The locations of tachykinins and NKRs
are consistent with the regulation of neuro-neuronal trans-
mission, motility, secretion, inflammation, and pain.
1. Neuro-neuronal transmission
Evidence for neuro-neuronal transmission, whereby neuro-
nal tachykinins activate NKRs on enteric neurons, derives
from studies of receptor trafficking and synaptic transmis-
sion. Stimulation of enteric nerves induces endocytosis of
the NK1R in myenteric neurons, which requires neuronal
conduction, SP and NKA release, and NK1R activation
(109, 316). Tachykinins generate slow excitatory postsyn-
aptic potentials in enteric neurons by activating NK1R and
NK3R (5).
2. Motility
SP andNKAmediate excitatory transmission via NK1Rs on
interstitial cells of Cajal and NK2Rs on smooth muscle
(305). In interstitial cells of Cajal, SP activates a nonselec-
tive cation channel that controls pacemaker functions (69)
and aNa-leak channel that mediates depolarization (149).
Given the importance of interstitial cells of Cajal inmotility,
targeting these mechanisms could be treatment of motility
disorders. HK-1, which is produced by immune cells, con-
tracts circular muscle of mouse colon primarily by activat-
ing the neuronal NK1R, with a minor contribution of
NK2Rs onmyocytes (155). However, in segments of human
colon, SP, NKA, and NKB all stimulate contraction of cir-
cular muscle by activating the NK2R on colonic myocytes
(228).
Mechanical stimulation of the mucosa evokes release of SP
and NKA, which partly mediate ascending contraction of
peristalsis by NK1R- and NK2R-dependent mechanisms
(76). Glial cell line-derived neurotrophic factor augments
SP release to enhances its contractile actions (114). Given
the role of SP in peristalsis, defects in tachykinin innervation
could contribute to abnormal motility. There is a reduced
density of SP-positive fibers in colonic circular muscle of
children with slow transit constipation, which could ex-
plain the dysmotility (152). Conversely, the density of
tachykinin-positive nerve fibers is increased in ileal myen-
teric ganglia of diabetic guinea pigs, which correlates with
enhanced release of acetylcholine and tachykinins, and in-
creased sensitivity of smooth muscle (58).
3. Secretion
Tachykinins stimulate electrolyte and fluid secretion from
the intestinal epithelium by activating NKRs on epithelial
cells, enteric neurons, or immune cells. This mechanism
facilitates propulsion and mediates protective secretory re-
sponses to infection. Cryptosporidiosis is a diarrheal disor-
der caused by the protozoan parasiteCryptosporidium par-
vum. Although self-limiting in healthy subjects, diarrhea
can be severe in immunocompromised patients. SP and the
NK1R are upregulated in the jejunal mucosa of macaques
infected with C. parvum and mediate increased Cl secre-
tion and glucose malabsorption (124). Thus NK1R antag-
onists may be useful to treat the symptoms of cryptospori-
diosis and other infections of the intestine.
4. Inflammation
A wealth of evidence implicates tachykinins in intestinal
inflammation, including plasma extravasation, granulo-
cyte influx, generation of proinflammatory cytokines,
and tissue damage (FIGURE 8). Inflammation correlates
with NK1R activation (see sect. IIID) and upregulation
(see sect. IIIE), and SP and the NK1R activate proinflam-
matory signaling pathways in colonocytes (see sect. IIIC).
NK1R blockade or deletion abrogates intestinal inflam-
mation induced by Clostridium difficile toxin A (53),
TNBS (80), and piroxicam in IL-10 knockout mice (348).
Tachykinins also participate in the inflammatory re-
sponses to infection, including formation of granulomas,
sites of chronic inflammation that prevent spread of in-
fectious agents (346). Together, these findings suggest a
role of NKR antagonists in intestinal inflammatory dis-
eases (see sect. VD).
SP and the NK1R also contribute to the aftermath of inflam-
mation, including fibrosis and healing. The NK1R is ex-
pressed by fibroblasts in the chronically inflamed mouse
TACHYKININS AND NEUROKININ RECEPTORS
277Physiol Rev • VOL 94 • JANUARY 2014 • www.prv.org
colon and in tissues from patients with Crohn’s disease,
where SP stimulates collagen synthesis (156). SP also pro-
tects colonocytes from apoptosis (159) and promotes ex-
pression of cysteine-rich angiogenic inducer 61 in the co-
lonic epithelium, which contributes to healing (157). Con-
sistent with these effects, NK1R deletion hampers healing of
themucosa after chronic colitis (52). Thus SP and theNK1R
have dual roles in intestinal inflammation, orchestrating
inflammation yet mediating repair. The potential beneficial
effects of NK1R antagonists in IBD could, therefore, be
offset by disrupted healing of inflamed tissues.
Tachykinins mediate intestinal inflammation induced by
activation of TRP channels of primary spinal afferent neu-
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FIGURE 8. Contributions of tachykinins and neurokinin receptors to neurogenic inflammation and pain. 1:
Noxious stimulation of peripheral tissues leads to the release or generation of multiple factors that derive from
the circulation, immune cells, and epithelial tissues. These can include proteases (e.g., mast cell tryptase),
growth factors (NGF), peptides (bradykinin), lipids (prostaglandins), amines (5-hydroxytryptamine), purines
(ATP), ions (protons), pressure, and elevated temperature. 2: These factors can activate several classes of
receptors and channels expressed by peptidergic nociceptors, including GPCRs, TRP channels, and receptor
tyrosine kinases (RTKs). 3: Activated nociceptors release neuropeptides in peripheral tissues, including SP and
NKA, which stimulate NK1Rs on endothelial cells of postcapillary venules and cause plasma extravasation and
granulocyte infiltration, and CGRP, which stimulates the calcitonin receptor-like receptor (CLR) on arterioles to
cause hyperemia. Together, these changes constitute neurogenic inflammation. 4: If the factors excite
nociceptors and generate action potentials, SP and CGRP are also released from the central projections of
nociceptors in superficial laminae of the spinal cord dorsal horn, where neuropeptides activate receptors on
spinal neurons to transmit painful stimuli centrally.
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rons. The TRPV1 agonist capsaicin induces SP release and
NK1R-mediated plasma extravasation in the mouse intes-
tine (96). Components of the inflammatory soup that acti-
vate TRP ankyrin 1 (TRPA1) include 4-hydroxy-2-nonenal,
formed when ROS peroxidate membrane phospholipids
(338), and cyclopentenone metabolites of PGD and PGE
(204). TRPA1 is expressed by primary sensory nerves inner-
vating the intestine and pancreas, where activation pro-
motes the release of SP and inflammation (56, 59). TNBS,
commonly used to evoke inflammation, covalently binds to
and activates TRPA1, which stimulates SP release and neu-
rogenic inflammation in the colon (88). Thus TRPA1 an-
tagonists could be a new therapy for colitis.
Mesenteric fat accumulates at sites of intestinal inflammation.
In humanmesenteric preadipocytes, SP induces NK1R-depen-
dent proinflammatory signals and has proliferative and anti-
apoptotic actions that could contribute to development of the
mesenteric fat that is characteristic of Crohn’s disease (144,
146). SP activation of the NK1R in adipose tissues may medi-
ate pathologies that are associatedwith obesity, including glu-
cose intolerance and insulin resistance, andNK1R antagonism
has anti-obesity effects in mice (145).
Fibrous adhesions within the abdominal cavity invariably oc-
cur after surgical manipulation of the intestine. Although usu-
ally benign, adhesions can impede transit, lead to visceral pain
and female infertility, and complicate further surgery. In line
with the proinflammatory actions of SP,NK1Ractivation dur-
ing surgicalmanipulation of the abdominal contents promotes
formation of adhesions by limiting fibrinolytic activity, which
allows fibrinous adhesions to persist (279). The NK1R antag-
onist aprepitant reduces adhesion formation in rats, support-
ing its therapeutic potential (188).
5. Pain
Colitis induces NK1R endocytosis in spinal neurons and
nocifensive behavior that are blocked by intrathecal NK1R
antagonist, consistent with SP release in the dorsal horn and
NK1R activation on spinal neurons that transmit pain (361)
(FIGURE 8) (see sect. IIID). The NK1Rmay also be activated
in pain-processing areas of the brain of patients with IBD
and irritable bowel syndrome (IBS) (135). A PET analysis of
binding of the NK1R-selective ligand [
18F]SPA-RQ revealed
reducedNK1R binding in cortical and subcortical regions in
patients with IBD and IBS. Several processes may account
for decreased binding of the NK1R ligand, including release
of endogenous SP and activation of the NK1R, displace-
ment of the ligand by endogenous SP, or reduced expression
of the receptor. Whatever the mechanism, the results sug-
gest a role for the NK1R in the human brain during pain.
Stress-evoked activation of the NK1R in the spinal cord and
intestine contribute to hyperalgesia and motility disorders.
The chronic psychological stress of water avoidance in rats
upregulates NK1R expression in neurons of superficial lam-
inae in the spinal cord, and induces an NK1R-dependent
visceromotor reflex to colorectal distention (42). Spinal mi-
croglial cells, p38 MAPK, and NF-B contribute to these
stress-induced changes. Thus water avoidance stress in rats
activates spinal microglial cells, as determined by phos-
phorylation of p38 MAPK in microglial cells in laminae I
and II of the spinal cord (43). Intrathecal administration of
minocycline (inhibitor of microglial cell activation) sup-
pressed stress-evokedp38phosphorylation,NF-Bactivation,
and NK1R upregulation, whereas intrathecal SB203580 (in-
hibitor of p38 MAPK) blocked stress-evoked NF-B activa-
tion but not NK1R upregulation. Notably, both minocycline
and SB203580 suppressed the visceral hyperalgesia in stressed
rats. Considered together, these results support a major role
for spinalmicroglial cells and p38MAPK inNK1R-dependent
visceral hyperalgesia (43). Whether activated microglial cells
release cytokines that upregulate the NK1R on spinal neurons
and cause central sensitization requires further investigation.
C. Respiratory Tract
The contributions of tachykinins to inflammation, hyperre-
activity, and secretion of the respiratory system have been
reviewed (231). This section reviews recent insights into the
debatable importance of tachykinins in the airways.
1. Neurogenic inflammation and airway
hyperreactivity
There is a sparse innervation of the airways by peptidergic
C- and A-fibers, although nerve terminals containing SP
and NKA supply the vasculature, smooth muscle, epithe-
lium, and secretory glands. Although neuropeptide-con-
taining sensory neurons innervating the nose and larynx
contribute to sneezing and cough, it is the proinflammatory
actions of SP and NKA that provided a major impetus for
the development of NKR antagonists to treat inflammatory
diseases of the airways.
As in many tissues, SP/NKA stimulate plasma extravasation
and granulocyte infiltration in the airways by activating the
NK1R in endothelial cells of postcapillary venules. Tachy-
kinins also stimulate secretion from airway seromucous
glands (283). Although these neurogenic inflammatory ef-
fects of tachykinins occur in the airways of most species,
there are marked interspecies differences in the ability of
tachykinins to alter tracheo-bronchial smooth muscle tone.
In the isolated guinea pig and human bronchus, exogenous
SP and NKA produce contraction that is mostly mediated
by the NK2R and partly by NK1R, which are coexpressed
bymyocytes (7, 95). In guinea pigs, SP andNKA also induce
relaxation due to activation of epithelial NK1R and release
of nitric oxide and prostaglandins, although this effect is
masked by the contractile component (95). However, in
rats and mice, where the contractile response is absent be-
cause NKRs are not expressed by airway smooth muscle,
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NK1R-mediated epithelium-dependent relaxation prevails
(201). After two decades of intense study, a role for endog-
enous tachykinins and the NK1R in airway hyperrespon-
siveness in allergen-stimulated mice has been proposed,
providing evidence for a major role of SP and the NK1R in
allergic hyperreactivity of the airways (123).
In the isolated guinea pig bronchus, electrical field stimula-
tion (EFS) or capsaicin causes nonadrenergic and noncho-
linergic (NANC) bronchoconstriction that is mediated by
tachykinins from sensory nerve endings. However, the sit-
uation is completely different inmice and rats, where EFS or
capsaicin provoke an epithelium- and tachykinin-depen-
dent bronchodilatation (106).Moreover, in the isolated hu-
man bronchus, there is no evidence that capsaicin affects
motor functions or that EFS stimulates a NANC contractile
and tachykinin-mediated effect. Although inhaled capsaicin
causes cough in healthy human subjects that is exaggerated
in asthmatic patients (318), there is no evidence that endog-
enous tachykinins cause bronchoconstriction in humans.
Despite this lack of evidence, the robust observation that
exogenous SP and NKA constrict the isolated human bron-
chus has strengthened the proposal that NKR antagonists
are a therapy for asthma and chronic obstructive pulmo-
nary diseases (COPD) (see sect. VE). However, the finding
that exogenous tachykinins cause bronchoconstriction does
not imply that endogenous tachykinins have the same ef-
fect. The failure of endogenous tachykinins to increase
bronchomotor tone in humans may be due to inadequate
release of tachykinins, release from nerve fibers supplying
cells that are distant from myocytes, or release from im-
mune cells that are resistant to EFS and capsaicin.Whatever
the explanation, the findings obtained by using exogenous
tachykinins continue to confound our comprehension of
the role of endogenous tachykinins in airway diseases.
2. TRP channels
Amajor advance in our understanding of neurogenic mech-
anisms of acute inflammation was provided by the report
that ,-unsaturated aldehydes, which are found in ciga-
rette smoke, can activate TRPA1 on peptidergic primary
sensory neurons of rodent airways (11). Activated TRPA1
triggers the release of SP and NKA that mediate neurogenic
inflammation in response to inhaled cigarette smoke. These
results are corroborated by the observations that other
components of cigarette smoke, including acetaldehyde and
nicotine, can also stimulate TRPA1 (22, 330). Indeed,
TRPA1 is a major target of reactive oxygen, nitrogen, and
carbonyl species. This unique sensitivity, coupled to the
selective expression of TRPA1 by peptidergic nociceptors,
suggests that TRPA1 is a neuronal sensor of oxidative
stress. Oxidative stress is not only increased in the respira-
tory tract by environmental agents, such as cigarette smoke,
but also occurs at sites of inflammation during the develop-
ment of asthma (38) and COPD (273). In ovalbumin-sensi-
tized mice, ovalbumin challenge induces airway hyperre-
sponsiveness and inflammation that is blunted by deletion
of TRPA1 (48). Thus TRPA1 is a neuronal sensor for fac-
tors that contribute to asthma and COPD, where activation
triggers the release of neuropeptides, including tachykinins,
that mediate neurogenic inflammation.
When inhaled, certain volatile anesthetics, including isoflu-
rane and desflurane, induce airway irritation, inflammation
and cough that can precipitate laryngospasm during anes-
thesia. TRPA1 has been implicated in these life-threatening
adverse reactions, as it mediates the irritant and inflamma-
tory effects of isoflurane and desflurane (87, 207, 292).
NK1R and NK2R antagonists block these inflammatory ef-
fects, which depend on TRPA1-dependent release of tachy-
kinins from primary afferent neurons in the airways (87,
207, 292).
The increased prevalence of asthma in infants and children
in the last 50 years is a mystery that cannot be explained by
the hygiene hypothesis. However, large epidemiological
studies have identified an association between the increased
prevalence of asthma with the growing use of acetamino-
phen in pregnant women, infants, and children (28). Al-
though the pathway that links acetaminophen use with
asthma is unknown, the N-acetyl-p-benzo-quinoneimine
metabolite of acetaminophen can activate TRPA1 by virtue
of its electrophilic nature, thereby provoking neurogenic
inflammation of the airways (230). Although clinical doses
of acetaminophen may promote moderate and reversible
neurogenic inflammation of the airways, repeated use, es-
pecially in susceptible individuals with reduced levels of the
endogenous ROS scavenger glutathione, may favor the de-
velopment of the asthmatic phenotype (230). Of relevance
for this hypothesis is the suggestion that the ability of N-
acetyl-p-benzo-quinoneimine to stimulate and desensitize
TRPA1 is the major mechanism for the analgesic action of
acetaminophen (10).
In addition to the established pathway by which reactive
molecules initiate tachykinin-mediated neurogenic inflam-
mation in the airways via TRPA1, SP released from sensory
nerve terminals increases ROS generation by a NK1R-de-
pendent mechanism. Thus NK1R antagonism reduces ROS
formation, epithelial damage, and subsequent remodeling in
allergen-challenged guinea pigs (319), and SP induces NK1R-
dependent neurogenic inflammation, oxidative stress, and
proinflammatory responses in rats (185). Given the role of
oxidative stress in thermal injury (221), it is of interest that an
NK1R antagonist prevents pulmonary inflammation evoked
by local burn injury (311).
Tachykinins may also participate in abnormalities of
cough. Coughing subjects have elevated levels of calcitonin
gene-related peptide (CGRP) and SP in nasal secretions
(187). TRPA1 may contribute to abnormal cough since
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agonists cause cough in guinea pigs and humans (12, 36),
and TRPA1mediates the cough response to cigarette smoke
(11). In common with other TRP channels, TRPA1 desen-
sitizes after activation (290). The observations that smok-
ing cessation leads to prompt enhancement of cough sensi-
tivity, even after many years of smoking, and that suppres-
sion of cough reflex sensitivity is caused by resumption of
cigarette smoking (312), may relate to the ability of ciga-
rette smoke to activate and desensitize TRPA1. Although
the role of tachykinins in these phenomena remains to be
determined, an enhanced secretion of SP mediated by in-
creased nitrosative stress could contribute to chronic cough
hypersensitivity (18).
In addition to neurons, TRPA1 is expressed by airway epi-
thelium, smooth muscle, and fibroblasts, which can con-
tribute to inflammation by releasing cytokines (232). The
possibility that tachykinins, which can also release cyto-
kines from airway epithelial cells (165), synergize with
TRPA1 to control cytokine production remains to be stud-
ied. Moreover, SP expression may not be restricted to sen-
sory nerves, since airway epithelial cells expressTac1 (323),
and cells of the hematopoietic lineage can secrete tachy-
kinins. Indirect evidence of this possibility derives from the
observation that immune complex-mediated and stretch-
induced lung injury are enhanced by the presence of the
Tac1 gene in hemopoietic-derived cells (62). Whatever their
origin, tachykinins, acting on the NK2R, can activate den-
dritic cell-mediated type 1 immune responses, thereby in-
creasing the production of IFN- and IL-2 production by
CD4() T cells (153). Overdistension of lung tissue during
mechanical ventilation can also evoke cytokine release, and
neuronal and nonneuronal SP contributes to ventilator-in-
duced lung inflammation and injury by an NK1R-mediated
mechanism (45). In this context, it is not surprising that
corticosteroids, the mainstream therapy of asthma, down-
regulate NK1R expression in airway myocytes of asthmatic
rats (184). Remodeling of the sensory innervation of the
airways may also contribute to inflammatory diseases. A
TNF--mediated increase in the levels of nerve growth fac-
tor (NGF) results in the proliferation of tachykinin-contain-
ing sensory nerve endings (329). NGF also contributes to
the tachykinin-mediated responses in rodent airways after
ozone inhalation (246), including during early life (131).
Finally, in a mouse model of allergic asthma induced by
house-dust mite antigen, NGF, primarily expressed in the
bronchial and alveolar epithelium, mediates the enhanced
release of SP, sensory innervation, and airway hyperrespon-
siveness (240).
3. Fluid secretion
The mortality of patients with cystic fibrosis is mainly due
to chronic bacterial infections of the airway that are favored
by the impaired reflex stimulation of mucus secretion from
submucosal glands. SP mediates the local responses to cap-
saicinoids through a mechanism involving coordinated ac-
tivation of cystic fibrosis transmembrane regulator and K
channels, which eventually results in secretion of fluid from
seromucous glands (132). While seromucous glands from
noncystic fibrosis patients respond to SP with increased se-
cretion, glands from cystic fibrosis patients are unrespon-
sive to SP (65). Similar findings were obtained in a pig
model of cystic fibrosis, where SP was unable to cause glan-
dular secretion (140). Thus defective secretory responses to
SP may contribute to the abnormalities in airway secretion
that underlie the pathology of cystic fibrosis.
D. Urogenital Tract
The role of tachykinins in urinary and reproductive tracts
and the therapeutic potential of NKR antagonists have been
reviewed (49, 247).
1. Urinary tract
Primary spinal afferent nerves containing SP and NKA in-
nervate the renal pelvic wall, ureter, and urinary bladder,
including the urothelium, muscle, and blood vessels (49). In
the wall of the renal pelvis, endothelin 1 (350) and PGE2
(163) stimulate SP release from sensory nerves, whereas
angiotensin counteracts the effects of PGE2 (162).
Tachykinins stimulate smooth muscle contraction of the
human ureter, mostly by activating the NK2R (138, 227,
255), suggesting the potential use of NK2R antagonists for
ureteral disease. In the urinary bladder, the NK1R is found
in blood vessels, the urothelium and muscle layers, with
some inter-species differences, and the NK2R is expressed
by detrusor muscle of all mammalian species studied, in-
cluding humans (49). In the rat, the NK1R couples to Rho
kinase, linking this receptor to smooth muscle contraction
(349). Patients with multiple sclerosis have increased den-
sity of SP-containing fibers in the urinary bladder, which
may contribute to detrusor overactivity in these patients
(271). NK1R antagonists are a potential therapy for over-
active bladder syndrome in postmenopausal women (299)
(see sect. VF), whereas NK2R blockade controls neurogenic
detrusor overactivity in rats with a spinal cord injury (1).
SP and NK1R have proinflammatory effects in the bladder.
In rats, bladder inflammation during early life induces an
upregulation of SP that persists into adulthood and is asso-
ciated with elevated micturition frequency, decreased mic-
turition volume, and enhanced vascular permeability (74,
300). Other proinflammatory actions of SP in the bladder
include stimulation of plasma extravasation and leukocyte
infiltration, mast cell degranulation, generation of ROS,
and expression of proinflammatory cytokines, chemokines,
adhesion molecules, and cyclooxygenase-2 (49). SP stimu-
lates expression of glucose-regulated protein 78, a receptor
for activated 2-macroglobulin, and blockade of this recep-
tor prevents SP-mediated bladder and urothelial inflamma-
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tion (339). TheNK1Rmediates the proinflammatory effects
of tachykinins in the mouse urinary bladder, since NK1R
blockade or deletion attenuates antigen-induced cystitis
(291). NK1R antagonists also prevent stress-induced
urothelial degeneration and mast cell degranulation in the
urinary bladder (89). Thus tachykinins contribute to the
clinical manifestations of interstitial cystitis, and NK1R an-
tagonists may be a treatment for inflammatory disorders of
the bladder.
There is a high degree of comorbidity between genitouri-
nary and gastrointestinal disorders that are characterized
by chronic pelvic pain. For example, colitis in rats is asso-
ciated with increased expression and release of SP and
CGRP in the urinary bladder that requires activation of
TRPV1 pathways (253).
2. Female reproductive system
Tachykinins and all NKRs are present in the uterus (57,
256). Their prevalence changes during pregnancy (256) and
is regulated by ovarian steroids (263). The NK2R is the
predominant tachykinin receptor involved in uterine con-
traction, and its activation is under tight regulation during
pregnancy (260). However, the NK1R in the uterus can medi-
ate inflammatory responses that may lead to abortion (93).
NKB is present in the human placenta, and increased pla-
cental levels of NKB and Tac3 could contribute to pre-
eclampsia and hypertension during late pregnancy (249,
250). Although placental levels of NKB increase during nor-
mal pregnancy and decline after delivery, they increase even
more after preterm labor (336), suggesting that regulation
of NKB during pregnancy is important for normal gesta-
tion. NKB may induce NK1R-mediated vasodilation of the
placenta during pregnancy and cause systemic NK3R-medi-
ated vasoconstriction that leads to hypertension. Elevated
NKB levels may be a diagnostic marker for preeclampsia,
and NK3R antagonists could be a therapy for this common
condition (247).
Within the ovary, tachykinins control steroid secretion and
may have an ancient role in stimulating oocyte growth (14).
Although tachykinins have been implicated in age-related
decline in reproductive function (357), their contribution to
control of reproductive capability remains to be fully de-
fined.
3. Male reproductive system
Tac1, Tac3, and Tac4 are expressed by human sperm, and
tachykinins increase sperm motility by NK1R- and NK2R-
dependent mechanisms (264). Sperm also express the SP-
degrading enzyme neprilysin, and neprilysin inhibition pro-
motes motility by inhibiting degradation of endogenous
tachykinins (264). The epididymis produces SP, which stim-
ulates sperm motility, and tachykinins potentiate contrac-
tility of the vas deferens (49). The importance of tachy-
kinins in testes development is illustrated by the finding of
severe testicular atrophy in dogs treated with a mixed NKR
antagonist at a young age (194).
The seminal vesicles are innervated by SP-containing fibers,
and SP induces contractions and facilitates neurally medi-
ated responses in this system (49). SP and NKA are present
at low levels in the rat and guinea pig prostate, abundant in
the dog prostate, but absent in humans (49). However,
Tac1, Tac3, andTac4mRNAs have been detected in human
prostate. The effects of tachykinins on prostate contraction
involve the NK1R in all species, but NK2R is dominant in
human (49).
SP is present in human erectile tissue and penile vessels and
can contract human erectile tissue (49). However, its role in
erection is unclear, since it has no effects in the cavernous
artery and relaxes norepinephrine-induced contractions of
corpus cavernosum and corpus spongiosum. NK1R antago-
nism suppresses ejaculation in rats in response to intraventric-
ular administration of a dopamine D3 receptor agonist (66).
E. Skin
The contribution of tachykinins to homeostasis and dis-
eases of the skin have been reviewed (FIGURE 9) (287).
1. Neuronal tachykinins
SP and NKA are present in primary sensory nerves in the
skin (70). Tachykinin-positive nerve fibers supply the der-
mis and epidermis as well as innervate dermal blood vessels,
keratinocytes, mast cells, dendritic cells, and hair follicles.
Many exogenous and endogenous factors can stimulate the
release of tachykinins from peripheral nerves in the skin,
including physical stimuli (heat, ultraviolet radiation,
scratching), allergens, and inflammatory mediators (brady-
kinin, prostaglandins, proteases, cytokines). Other factors,
for example, pituitary adenylate cyclase activating polypep-
tide-38, inhibit tachykinin release from cutaneous sensory
nerves, in line with their anti-inflammatory effects (236).
2. Keratinocytes
Mouse and human keratinocytes express NK1R and NK2R
(FIGURE 9) (315). The consensus of multiple studies is that
SP and NKA control the capacity of keratinocytes to serve
as cytokine factories by regulating production of proinflam-
matory cytokines (315). SP also upregulates NGF produc-
tion by keratinocytes and may thereby control the regener-
ation of cutaneous nerves under normal conditions and dur-
ing wound healing (47). In contrast to CGRP, SP has only a
moderate effect on keratinocyte proliferation (284). Nepri-
STEINHOFF ET AL.
282 Physiol Rev • VOL 94 • JANUARY 2014 • www.prv.org
lysin is expressed by keratinocytes and endothelial cells,
where it dampens the actions of tachykinins (245).
3. Cutaneous blood vessels
SP and NKA-positive nerve fibers innervate the vasculature
of the superficial dermis, where tachykinins activate the
NK1R on endothelial cells of postcapillary venules to stim-
ulate plasma extravasation, granulocyte infiltration, and re-
lease of proinflammatory mediators (neurogenic inflamma-
tion) (FIGURE 8). However, endothelial cells can also pro-
duce tachykinins, and NGF upregulates SP expression and
release from human dermal microvascular endothelial cells
(215). Although SP and NKA promote plasma extravasa-
tion from postcapillary venules, resulting in edema, recent
evidence suggests that while tachykinins maintain basal cu-
taneous microcirculation, pituitary adenylate cyclase acti-
vating polypeptide-38 mediates neurogenic inflammatory
vasodilation of arterioles and neuropathic mechanical hy-
peralgesia (40). In human dermal microvascular endothelial
Keratinocytes:
NK1R → NF-κB → cytokines, chemokines
NK2R → NF-κB → cytokines, chemokines
SP → NGF↑ , prolactin↓
Langerhans cells:
SP → T cell activation
Mast cells:
SP → TNFα, LktB4
Neutrophils:
ROS, MMPs
Fibroblasts:
SP release
Nerve terminal:
Ca2+, p38
NF-κB → ICAM↑
→ VCAM↑
IL1, IL-22 → NEP↑
SP ← IFNγ
NK1R
Sensory
nerve
SP
NKA
Neuropeptide release
immunomodulation
Neural Sensitization
Immunomodulation
Vasoregulation
Pain
Itch
FIGURE 9. Functions of tachykinins in the skin. SP and NKA are released from the peripheral endings of
primary sensory nerves in the skin. They act on keratinocytes via NK1R and NK2R to activate NF-B and
promote release of cytokines and chemokines. SP and NKA act within the vasculature to induce plasma
extravasation and to upregulate adhesion factors that stimulate neutrophil adhesion and infiltration. During
inflammation, SP and NKA activate mast cells, neutrophils, and Langerhans cells, which amplifies the inflam-
matory response. Centrally released tachykinins contribute to pain and itch transmission.
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cells, SP induces an NK1R-dependent upregulation of adhe-
sion molecules through activation of the transcription fac-
tors NF-AT and NF-B, which leads to the influx of inflam-
matory cells (269, 270).
4. Fibroblasts
Compared with other tissues, such as the airways, the role
of tachykinins in dermal fibroblasts is poorly understood.
Human dermal fibroblasts in culture express Tac1, which is
upregulated by exogenous SP (17), as well as the NK1R,
which is upregulated by interferon- (192). Thus tachy-
kinins may regulate fibroblasts by autocrine and neuronal
mechanisms to regulate proliferation and wound healing.
Indeed, SP induces an NK1R-dependent proliferation of hu-
man dermal fibroblasts (129). Human dermal fibroblasts
express neprilysin, which is augmented by IL-1 and IL-22
(351). Notably, neprilysin is upregulated in the skin and in
ulcers of patients with diabetes, which, combined with the
peripheral neuropathy, could contribute to impaired wound
healing (13).
5. Dermatitis and pruritus
The peripheral nervous system has long been implicated in
the pathophysiology of inflammation and itch in dermatitis.
Tachykinins are upregulated in the lesional skin of humans
and mice with atopic dermatitis (242). Studies in mice im-
plicate tachykinins and NKRs in the sensitization and in-
flammatory phases of allergic contact dermatitis. In amodel
of allergic contact dermatitis in mice, NK1R deletion or
antagonism attenuates the sensitization and inflammatory
responses to dinitrofluorobenzene (297). SP acting within
lymph nodes mediates the sensitization phase (302). Sur-
prisingly, NK2R antagonists enhanced the inflammatory re-
sponse, whereas NK2R agonists had the opposite effect,
suggesting a protective role of for the NK2R. Similarly,
repeated SP challenge resulted in an anti-inflammatory re-
sponse by modulating T cell and dendritic cell function in a
chronic stress-induced model of allergic contact dermatitis
(258). Whereas neprilysin disruption exacerbates allergic
contact dermatitis, it has no effect on irritant dermatitis in
mice (296). In summary, the contributions of tachykinins to
allergic contact dermatitis are not fully understood, with
evidence for pro- and anti-inflammatory functions.
SP is a major mediator of pruritus of atopic dermatitis, and
NKR antagonists have been proposed as a therapy for itch
(see sect. VG). SP induces expression of artemin, a member
of glial cell line-derived neurotrophic factors, by human
dermal fibroblasts, and artemin evokes warmth-evoked
scratching and thermal hyperalgesia in mice (222). As a
novel therapeutic strategy, ointment containing the nerve
repulsion factor semaphorin 3A reduces the density of in-
nervation of mouse skin with SP-containing nerve fibers,
attenuates inflammation, and suppresses pruritus in a
mouse model of allergic dermatitis (234).
TRP channels of sensory neurons innervating the skin also
contribute to inflammation and pruritus of contact derma-
titis. Notably, TRPA1 mediates the inflammation and
scratching behavior of mice exposed to haptens (oxazolone,
urushiol) and the allergen of poison ivy, and SP-induced
scratching behavior is not observed in Trpa1 knockout
mice (191).
6. Wound healing
Tachykinins have been implicated in wound healing, and
deficits in tachykinin innervation (266) and upregulation
of neprilysin (13) may contribute to the abnormal wound
healing that occurs in patients and animals with diabetes.
In a laser-induced wound healing model in rats, exoge-
nous SP was found to promote neurite outgrowth and
wound healing (77), and capsaicin also causes a NK1R-
dependent increase in NGF biosynthesis in the rat skin
(8).
7. Stress-induced hair loss
The hair follicle apparatus expresses tachykinins, NKRs,
and endopeptidases, and tachykinins have been impli-
cated in stress- and autoimmune-evoked hair loss. Stress-
induced premature induction of catagen and hair follicle
apoptosis in mice requires expression of the NK1R and
the presence of mast cells (15). Observations of human
skin biopsies and hair follicles in culture indicate that SP
downregulates production of prolactin, which is impor-
tant for hair growth (178). SP, NK1R, and neprilysin
regulate the inflammatory response in a murine model of
alopecia areata, an autoimmune disorder of the hair fol-
licle associated with inflammatory cell influx around
growing hair follicles (306).
F. Neurogenic Inflammation and Nociceptive
Transmission
Primary sensory neurons innervate most tissues and can
release tachykinins from peripheral and central endings to
induce neurogenic inflammation and pain transmission.
This section discusses the mechanisms and importance of
tachykinins in these processes.
1. Tachykinins in primary sensory neurons
The localization of tachykinins in a subset of primary sen-
sory neurons of the trigeminal, dorsal root, and vagal gan-
glia has been a topic of great interest for the past 60 years
since SP and NKA have been proposed to play a major role
in transmission at the level of the first synapse in the noci-
ceptive pathway. Tachykinin-containing neurons in sensory
ganglia have small cell bodies with unmyelinated C-fibers or
thinly myelinated A-fibers and slow conduction velocities.
These neurons mediate nociceptive responses to physical
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(thermal, mechanical) and chemical stimuli. In addition, by
releasing neuropeptides from peripheral endings, they gen-
erate “neurogenic inflammation,” which includes arteriolar
dilatation and plasma extravasation and granulocyte infil-
tration from postcapillary venules (FIGURE 8). SP- and
NKA-expressing neurons, representing 30–50%of neurons
of the rat DRG, coexpress multiple neuropeptides that have
been detected by immunochemical techniques. However,
convincing evidence for neuropeptide release from the cen-
tral or peripheral nerve terminals, a prerequisite for physi-
ological function, is available for only a limited number of
neuropeptides, notably SP and CGRP (44).
Peptidergic sensory neurons express TRP ion channels, in-
cluding the thermosensors TRPV1, TRPV2, TRPV3, and
TRPV4, the menthol sensor TRPM8, and the irritant sensor
TRPA1. Once activated, TRP channels induce release of
neuropeptides, including tachykinins. The observation that
chronic treatment with the TRPV1 agonist capsaicin de-
pletes neuropeptide from sensory nerve terminals implies
that all peptidergic neurons express TRPV1. Moreover,
TRPA1-positive neurons are a component of the TRPV1
neuronal population (324), with TRPA1 localized to pepti-
dergic neurons (34). However, a proportion of nonpepti-
dergic neurons express TRPA1 (150). Mature sensory neu-
ropeptides are produced from pre-pro-hormones synthe-
sized in the neuronal cell body to be transported by active
mechanisms to both central and peripheral nerve endings,
where they are stored in dense-core vesicles. Neurotro-
phins, including NGF, regulate the expression of neuropep-
tides by sensory neurons, as well as the development of the
neurons themselves (314).
Two modes of neuropeptide release from peripheral termi-
nals of peptidergic sensory neurons have been identified.
The first, induced in vitro by EFS and putatively in vivo by
antidromic invasion of a propagated action potential to the
terminal region of nerve fibers, results in a tetrodotoxin-
sensitive and neuropeptide-mediated response. This path-
way offers a neurochemical and ionic basis for the seminal
hypothesis of Bayliss (27) and Lewis (182), whereby injury
induces a neurogenic flare response, which we now know is
mediated by CGRP released from cutaneous perivascular
sensory nerves (309). The TRPV1 agonist capsaicin acti-
vates the second tetrodotoxin-insensitive pathway of neu-
ropeptide release, providing insights into the function of
peptidergic sensory neurons (326). An identical differentia-
tion exists in the activation of neuropeptide release from
central endings of primary sensory neurons in response to
peripheral noxious stimuli (328). However, while there is
no doubt that the release of neuropeptides from peripheral
endings of sensory neurons causes neurogenic inflamma-
tion, there is uncertainty of the pathophysiological impor-
tance of centrally released tachykinins to nociceptive trans-
mission.
1. NKR activation in DRG and spinal cord
NKRs are expressed by neurons of the DRG and dorsal
horn of the spinal cord. Primary sensory neurons express
both NK1R and NK2R that may serve as autoreceptors for
SP and NKA released from the same neurons. Thus Ca2-
dependent release of SP enhances TRPV1 activity of DRG
neurons in an autocrine manner by activating neuronal
NK1R and NK2R (298, 360). PKC- mediates NK1R-de-
pendent sensitization of TRPV1, probably by phosphory-
lating TRPV1 and altering channel gating (360). The NK1R
andNK2R are also expressed by neurons of the dorsal horn,
where SP/NKA released from the central projections of pri-
mary sensory neurons can activate NKRs on spinal neurons
and induce endocytosis (see sect. IIID). Additionally, medi-
ators released locally within the spinal cord may stimulate
tachykinin release and thereby activate spinal NKRs. Thus
spinal cytochrome P-450 activity can generate 5=,6=-
epoxyeicosatrienoic acid, which activates TRPV4 on DRG
neurons to release sensory neuropeptides (134, 344). One
consequence of NK1R activation is the formation of ROS
(104, 319). In DRG neurons, the intracellular ROS-
mediated pathway augments M-type K channels and
thereby counterbalances the ability of SP to sensitize
TRPV1 and induce thermal hypersensitivity (190). This
mechanism may explain the finding that SP causes hyperal-
gesia but not acute nociception. However, the sensitizing
effect of SP on neurons is not confined to TRPV1, since
NK1R activation also sensitizes P2X3 channels of trigemi-
nal nociceptive, nonpeptidergic neurons (254).
2. Tachykinin-induced transmission in the dorsal
spinal cord
A large body of evidence supports the view that SP and the
NK1R contribute to nociception and hyperalgesia in exper-
imental animals (FIGURE 8). Thus Tac1 deletion attenuates
moderate to intense pain and prevents neurogenic inflam-
mation (50), and NK1R deletion suppresses stress-induced
pain (73). However, NK1R antagonists have failed as anal-
gesics in clinical trials (126), and it is now recognized that of
all the neuropeptides released by C-fibers, CGRP is a more
likely contributor to pain typical of migraine headaches
(31). However, despite the negative results of clinical trials,
preclinical studies still support a role for SP and NKRs in
the modulation of pain and hyperalgesia, although their
role may be more subtle than that previously proposed.
Normally, A and C fibers transmit pain while A fibers
signal touch. However, after nerve injury, A fibers can
transmit pain. In models of inflammatory and neuropathic
pain, SP is upregulated in large-diameter neurons (237).
Intraplantar injection of carrageenan leads to spinal pro-
duction of 12-lipoxygenase-derived hepoxilin A3, which
enhances release of SP and contributes to inflammatory hy-
peralgesia via TRPV1 and TRPA1 (113). In a chronic con-
striction model of nerve injury, the NK1R is upregulated in
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spinal neurons, which could also amplify pain (71). Studies
of Tac1-deficient mice reveal a contribution of SP to pain-
related behavior induced by intraplantar Formalin and cap-
saicin, although the contribution of SP is small and transient
(29). In a mouse model of peripheral diabetic neuropathy,
increased SP expression in the presynaptic sensory fibers inner-
vating lamina I-III has been found in association with en-
hanced ERK1/2 phosphorylation and induction of other
markers of activation of the nociceptive pathway (72).
Intraplantar and intrathecal pretreatment with the NK1R
antagonist CP96345 inhibits mustard oil-induced thermal
hyperalgesia and nocifensive behaviors (229). Peripheral
inflammation induced by intraplantar Formalin activates a
cascade of intracellular events in NK1R-positive spinal neu-
rons that can lead to hyperalgesia, including PI3K, Akt, and
the mammalian target of rapamycin (mTOR) (353), which
have previously been observed in DRG and spinal cord
neurons (352). Intraplantar carrageenan also induces
NK1R-dependent activation of PI3K and Akt in dorsal horn
neurons (64).
Several analgesics have been proposed to act by modulating
peptidergic sensory neurons. Among a series of Ca2 chan-
nel antagonists, only ziconotide reduced NK1R internaliza-
tion evoked by noxious stimulation (328). The vesicular
glutamate transporters in Nav1.8Cre-positive neurons and
SP are required for Formalin-evoked nociception (171). In-
trathecal botulinum neurotoxin B inhibits SP release from
spinal primary afferent sensory fibers and attenuates the
ensuing nociceptive response in models of inflammatory
and neuropathic pain (130).
Finally, SP has been linked to intrinsic spinal cord pathways
that modulate pain as indicated by the observation that
descending facilitation from rostral ventral medial medulla
contributes to facilitation of nociceptive transmission and
hyperalgesia via NK1Rs (46). An opposing function has
been reported for SP in the locus coeruleus, where NK1R
activation facilitates spinal noradrenergic transmission and
attenuates mechanical allodynia after chronic constriction
injury (226).
G. Immune System
Tachykinins and their receptors are expressed by multiple
immune cells, where they participate in inflammatory re-
sponses and immunity.
1. Neutrophils
SP regulates the activity and function of neutrophils and can
control their production and infiltration into inflamed tis-
sues. Thus SP stimulates the generation and release of cyto-
kines, chemokines, matrix metalloproteases, and ROS from
neutrophils and promotes bacterial phagocytosis (16, 244).
Treatment of neonatal rats with capsaicin depletes the levels
of SP in bone marrow, yet enhances neutrophil generation
and release, whichmay be related to enhanced expression of
Tac1 and Tacr1 by bone marrow cells (99). While some
reports fail to demonstrate a role for theNK1R in cutaneous
neutrophil recruitment (262), others have shown that
NK1R antagonism attenuates neutrophil influx (295), sug-
gesting selective involvement of the NK1R under different
experimental conditions.
2. Monocytes and macrophages
There is convincing evidence for a role of tachykinins in
regulating macrophage function during wound healing,
inflammation, autoimmunity, and infection (266, 354).
Moreover, NKR expression by macrophages is affected in
certain disorders. For example, hypoxia in rats upregulates
NK1R expression by pulmonary macrophages (359), and
the NK1R is upregulated by threefold in macrophages of
smokers compared with nonsmokers (26). In a patient with
myelofibrosis, which is often associated with inflammatory
and neoplastic conditions, increased levels of SP and TGF-
were observed (121). Finally, Tac4 mRNA, which encodes
HK-1, is present in CD11b macrophages and CD11c
dendritic cells in mice, suggesting a role of macrophage- or
DC-derived HK-1 in immunoregulation (235).
3. Dendritic cells
Dendritic cells (DC) coordinate the activation of antigen-
specific effector andmemory lymphocytes, and thereby play
amajor role in acquired immunity. Bothmurine and human
DCs express functional NK1R (238) and NK2R (153),
where activation engages the NF-B pathway and regulates
T-cell function. SP and the NK1R are critically involved in
controlling the immunoregulatory role of Langerhans DCs
of the mouse skin (205). Human Langerhans cells also ex-
press SP (321), which may control T-cell proliferation (176)
and regulate other dermal cells, such as keratinocytes.
Tachykinins have been implicated in stress-evoked altera-
tions in immunity. Thus acute immobilization stress of mice
exacerbated cutaneous infection with Leishmania, which
correlated with decreased numbers of epidermal Langer-
hans cells and greater SP immunoreactivity in skin (289). In
the lung, SP regulates pulmonary responses to inhaled an-
tigens by promoting the recruitment of DCs (166).
4. Mast cells
Mast cells are closely associated with SP-positive sensory
nerves in many tissues, and there is a bidirectional commu-
nication between mast cells and primary sensory neurons,
whereby sensory neuropeptides stimulate mast cells, and
mast cell products control neuropeptide release. SP induces
the release of TNF- (78) and vascular endothelial growth
factor (301) frommast cells, thereby contributing to inflam-
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mation, immunity, and angiogenesis. SP also induces Ca2
signals and leukotriene B4 release from mast cells, but only
when co-cultured with fibroblasts (243). However, other
studies suggest that SP stimulates the release of preformed
mediators, such as histamine, from skin mast cells, but does
not affect the transcription of cytokine genes (115). The
NK1R also mediates stress-evoked mast cell degranulation
in rat skin (90).
5. Eosinophils
Like mast cells, eosinophils are also found in close proxim-
ity to SP-positive neurons in inflammatory diseases (313).
However, the pathways that lead to eosinophil activation
by tachykinins or the production of tachykinins by eosino-
phils are poorly understood and may involve epithelial cells
(139). In the skin, SP-induced eosinophil infiltration is un-
der the control of mast cell stimulation (239). In a model of
allergic asthma in mice, NK1R activation promotes the re-
lease of leukotriene B4 and eosinophil recruitment (4), and
in a guinea pig model of asthma, SP and NKA concentra-
tions correlate positively with higher numbers of eosino-
phils (267).
6. Lymphocytes
T cells synthesize SP and express the NK1R during inflam-
mation and infection, and SP regulates T-cell proliferation,
cytokine and chemokine release, and killer activity (343).
This regulation may be important in the development of
autoimmune conditions such as type 1 diabetes, where T
cell-mediated death of pancreatic beta cells causes insulin
deficiency. For example, pancreatic sensory nerves that ex-
press TRPV1 are required for the development of islet in-
flammation and insulin resistance in diabetes-prone mice,
whereas SP delivery to the pancreas reverses insulin resis-
tance, inflammation, and diabetes (277). SP and the NK1R
also regulate release of cytokines in autoimmune encepha-
lomyelitis in mice (280). Both HK-1 and the NK1R are
found in murine B cells and can regulate B-cell development
and differentiation, probably in an autocrine fashion (111,
362).
7. Natural killer cells
Natural killer cells of rodents and humans express NK1R
and respond to SP (92). SP enhances cytotoxicity of natural
killer cells (177), promoting release of cytokines (186). The
protective actions of SP against certain tumors and viruses
may depend on activation of natural killer cells and T cells
(197).
H. Cancer
Many types of tumor cells express NKRs, and tachykinins
from tumor cells or infiltrating nerves or immune cells can
influence proliferation, apoptosis, and metastasis of tumor
cells in an autocrine, paracrine, or neurocrine manner.
1. Neural cancer
Neural tumors and cell lines often express tachykinins and
the NK1R (119, 179, 219). The NK1R activates signaling
pathways in U373MG cells that are related to growth and
survival (see sect. IIIC). Notably, NK1R blockade reduces
basal Akt phosphorylation, which suggests expression of a
constitutively active receptor in glioblastoma cell lines (3).
HK-1 also causes NK1R-mediated expression of the matrix
metalloproteases by glioma cells, which promotes migra-
tion (217). NK1R antagonists may be a therapy for neural
tumors since blockade reduces growth of U373MG cells
xenografts (252).
Neuroblastoma is a sympathetic nervous system-derived
childhood tumor with a poor prognosis. SY5Y and
CHP212 neuroblastoma cell lines express full-length and
truncated NK1R as well Tac1, and NK1R silencing blocks
mitogenesis (218). Interestingly, stimulation of P2X7 nucle-
otide receptor triggers proliferation of neuroblastoma cell
lines in part due to SP release, suggesting the existence of an
autocrine pathway (272). Thus NK1R antagonists could be
a therapy for neuroblastoma.
2. Colon cancer
Colon cancer is the leading cause of death among gastroin-
testinal diseases.Multiple observations support the involve-
ment of SP and the NK1R in proliferation and tumorigene-
sis in the colonic epithelium. In human NCM460 colonic
epithelial cells, SP activates multiple signaling pathways
that are linked to proliferation (see sect. IIIC). The NK1R is
expressed in SW-403 colorectal cancer cells, and the NK1R
antagonist L-733,060 blocks proliferation in these cells
with and without exogenous SP, suggesting existence of an
autocrine mechanism (288). The truncated NK1R is prefer-
entially upregulated in colonic epithelial cells of patients
with ulcerative colitis who develop colonic carcinoma, sug-
gesting a functional role for the truncated NK1R in trans-
formation (108). The diminished desensitization and endo-
cytosis of the truncated NK1R could amplify its tumori-
genic potential.
The inactivation of tumor suppressor genes, often associ-
ated with promoter hypermethylation, can be exploited to
identify novel tumor suppressor genes. Importantly, Tac1
was found to be a frequent target of methylation in primary
colon cancers (47%) (216). The intensity of Tac1 methyl-
ation was higher in Dukes A/B than in Dukes C/D cancers
and was associated with a small but significant downregu-
lation of Tac1mRNA inMSI-high colon tumors, indicating
that Tac1 expression is reduced in colon carcinogenesis
through hypermethylation.
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3. Pancreatic cancer
Pancreatic cancer has the lowest survival rates of any gas-
trointestinal malignancy. The NK1R is upregulated in hu-
man pancreatic tumors, especially in advanced tumors with
a poor prognosis (101). Several pancreatic cancer cell lines
also express the NK1R, and SP exposure stimulates growth
of these cells by an NK1R-dependent process (101).
4. Breast cancer
Cell lines and malignant breast biopsies have increased lev-
els of Tac1, NK1R, and NK2R mRNA and produce high
levels of SP (35, 310). Studies of human breast carcinoma
cells in culture and after xenograft implantation into mice
indicate that NK1R and NK2R antagonists inhibit growth
by a cytostatic mechanism, in both the presence and absence
of exogenous SP and NKA (35). The RE-1 silencer of tran-
scription (REST) is a transcriptional regulator that, to-
gether with NF-B, suppresses Tac1 gene expression in
non-neuronal cells (112). REST inhibits Tac1 in breast can-
cer cell lines and in primary breast cancer cells, suggesting
an important role for REST in the oncogenic function of SP
(278). Immunoneutralization of SP strongly inhibits MAPK
activation, cell cycle progression, and growth of breast can-
cer cell lines, while promoting apoptosis (208). Overexpres-
sion of the short form but not the full-length NK1R induces
transformation of breast cancer cells, suggesting that tar-
geting the truncated version of this receptor could be a
therapeutic strategy, if achievable (257).
5. Lung cancer
Small cell lung cancers express a variety of neuropeptides
that can act as autocrine growth factors. NKA has been
detected in small cell lung cancers lines (32), and Tac1 and
its products are present in some lung cancers (37). NK1R
antagonism or deletion predisposes the development of
bleomycin-associated lung adenocarcinoma (196). Block-
ade of the NK1R in mice treated with bleomycin also affects
cytoplasmic translocation of the death receptor Nur77 and
alters expression of Bcl2 and Bak, which are associatedwith
apoptosis. Consistent with these observations, treatment of
mice with aerosolized SP impedes cigarette smoke-induced
lung damage and tumor development, and reverses cellular
and genetic precursors of emphysema and malignancy
(120).
6. Skin cancer
SP and the NK1R are expressed by melanomas and mela-
noma cell lines (148, 220). NK1R blockade inhibits growth
and apoptosis of melanoma cells, in the presence or absence
of SP, indicating an autocrine SP/NK1R system (220).
While SP and the NK1R can directly promote melanoma
cell growth, NK1R signaling may indirectly suppress mel-
anoma development in vivo. SP infusion protects mice
against melanoma cell growth, and this protection is lost
in mice depleted of T and natural killer cells (197). The
adoptive transfer of these cells from SP-treated mice also
suppressed tumor growth, suggesting that SP can prime
the immune system to defend against melanoma tumori-
genesis.
V. THERAPEUTIC POTENTIAL OF
NEUROKININ RECEPTOR ANTAGONISTS
A. Overview
Preclinical studies implicating tachykinins in diverse path-
ological processes (see sect. IV) spurred intense efforts by
the pharmaceutical industry to develop NKR antagonists.
These efforts were highly successful. Over 500 patents for
NKR antagonists have been filed during the last 20 years,
and some compounds have been evaluated in clinical trials.
Despite intensive efforts, there is but one success: approval
of the NK1R antagonist aprepitant (EMEND
T) and its pro-
drug fosaprepitant (IVEMENDT) to treat chemotherapy-
induced nausea and vomiting (CINV) and postoperative
nausea and vomiting (FIGURE 3D) (118). Other large-scale
trials of NKR antagonists for diverse conditions have either
failed to demonstrate a benefit compared with existing ther-
apies or placebo, or the results have been equivocal. In other
areas, such as pruritus and viral infection, small-scale trials
show promise, and large studies are necessary to determine
the clinical utility. Finally, there are some indications, such
as postsurgical formation of fibrous adhesions and cancer,
where studies in animals show that NKR antagonists are
effective treatments, but data from humans are lacking.
The challenges of developing NKR antagonists to treat hu-
man diseases are formidable, and there aremultiple possible
reasons for the failure. Many of the disease targets are
poorly understood, with unknown etiology and complex
pathology. There are obvious caveats in extrapolating the
results from experimental animals to humans. Some animal
models faithfully recapitulate human disorders, including
models of nausea and emesis, where NK1R antagonists are
effective in multiple species, including humans. However,
this is not usually the case, and the difficulties of developing
an animal model of a human disorder of unknown cause are
daunting. The challenge of extrapolating from animal to
human studies is complicated by differences in the potency
with which certain antagonists interact with NKRs of dif-
ferent species (98). The molecular nature of the interactions
between antagonists and receptors can markedly influence
efficacy. Considerations include whether antagonists inter-
act with the same sites as the endogenous agonists (or-
thosteric), or whether they bind to different sites and
thereby alter receptor interactions with endogenous tachy-
kinins (allosteric). Whereas orthosteric antagonists shut
down signaling, allosteric antagonists fine-tune signaling by
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endogenous tachykinins and thereby exert more subtle and
perhaps beneficial effects. Whether drugs are neutral antag-
onists (no effects in the absence of agonist), inverse agonists
(decrease basal activity of constitutively active receptors),
or insurmountable antagonists (sustained interactions with
receptors) can also affect the outcome. The redundancy
inherent in the tachykinin system also complicates thera-
peutic strategies. When one receptor is antagonized, the
other two may compensate, and antagonists that target two
or more NKRs, or even NKRs and other GPCRs, could be
necessary. Interactions between NKRs and other GPCRs
adds complexity since receptor heterodimers exhibit dis-
tinct signaling properties and likely pharmacology (261).
Finally, there are challenges of targeting antagonists, not
only to appropriate tissues but also to appropriate subcel-
lular domains. PET imaging with labeled antagonists en-
ables verification of central penetrance, allowing optimiza-
tion of dosing regimens for effective drug occupancy of
brain NK1Rs. However, the subcellular targeting of antag-
onists to block NKR signaling from specific subcellular do-
mains has not been given similar attention. NKRs traffic to
different subcellular compartments from which they can
transmit unique signals with distinct outcomes (223). Thus
targeting antagonists to defined subcellular compartments,
possibly by lipidation of antagonists, could allow more se-
lective antagonism, with fewer side effects than global an-
tagonism of all signaling events.
Despite these disappointments, the pharmaceutical interest
has not waned, as reflected by the numerous and continued
efforts to develop antagonists of all three NKRs, and the
large number of ongoing clinical trials. This section high-
lights the successes and failures of clinical trials of NKR
antagonists. The development of NKR antagonists has been
reviewed (6).
B. CINV
Cytotoxic chemotherapy is the mainstay treatment for can-
cer, with the debilitating and feared side effects of nausea
and vomiting. Although steroids and antagonists of sero-
tonin 5-HT3 and dopamine D2 receptors are effective treat-
ments for the initial nausea, they are ineffective against the
later phases. The realization that SP is concentrated in brain
areas involved in vomiting (9), coupled with the findings
that NK1R antagonists block emesis induced by peripher-
ally and centrally acting emetics (345), provided the impe-
tus for development of NK1R antagonists as treatments for
CINV. Studies in humans substantiated these findings in
animals, confirming the predictability of animal models
(125). The development of PET tracers for brain imaging in
humans verified central penetrance of peripherally admin-
istered NK1R antagonists and facilitated the design of dos-
ing regimens for aprepitant that allowed blockade of90%
of the targeted receptors (118). In patients receiving cispla-
tin-based chemotherapy, aprepitant combined with the
standard treatment of ondansetron (5-HT3 antagonist) and
dexamethasone provided better antiemetic protection than
the standard regimen alone (265). Aprepitant was approved
in 2003 for oral administration in combination with the
standard regimen. Fosaprepitant, a prodrug of aprepitant,
was approved for intravenous use to treat CINV in 2008,
and aprepitant was approved to treat postoperative nausea
and vomiting in 2006. A recent review of multiple trials of
NK1R antagonists for treatment of emesis confirmed their
effectiveness but also revealed that use may be associated
with increased rates of infection, suggesting that ongoing
safety assessment is required (82).
C. Affective and Addictive Disorders
The development of NKR antagonists to treat the stress-
related disorders has been reviewed (86). The presence of SP
in brain areas involved in emotion and affective functions,
and its colocalization with serotoninergic and noradrener-
gic transmitters that regulate emotions, suggest involve-
ment of tachykinins in affective disorders. Thus immobili-
zation stress in rats induces SP release in the medial nucleus
of the amygdala, and central administration of an NK1R
antagonist blocks stress-evoked anxiogenic-like behavior
(85). A role for tachykinins in depression was provided by
the report that NK1R blockade suppressed depressive be-
havior in guinea pigs and that the NK1R antagonist MK-
869 had antidepressant effects in patients with moderate to
severe major depression (167). Phase II trials confirmed
effectiveness of NK1R antagonists to treat depression (86).
However, a large placebo-controlled multisite phase III trial
of patients with major depressive disorder did not confirm
the efficacy of MK869, despite a dosing regimen that
achieved near-maximum receptor occupancy in the brain
(147). Although subsequent trials confirmed these results,
the findings are difficult to interpret since the drugs selected
as a positive control were also no more effective than the
placebo. Recent trials also failed to show beneficial effects
of NK1R antagonists in posttraumatic stress disorder and
generalized anxiety (206, 214).
The lack of efficacy of antagonists in depression may relate
to patient heterogeneity, assessment of end-points, and
pharmacokinetic properties of the antagonists. A compari-
son of the NK1R antagonists aprepitant, CP-99994, and
ZD6021 suggests that slow functional reversibility is asso-
ciated with long-lasting in vivo efficacy of NK1R antago-
nists, and may be an important determinant of therapeutic
potential (189). A recent clinical trial of the efficacy of the
NK1R antagonist orvepitant to treat major depressive dis-
order supports this proposal (276).
Antagonists of other NKRs may be of value for stress-re-
lated disorders. NK3R antagonists may be effective treat-
ments for schizophrenia and schizoaffective disorder (211),
panic attacks, and Parkinson’s disease (308). Antagonists of
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the NK2R have been shown to be effective in clinical trials
for the treatment of major depression (86).
The NK1R has been implicated in addiction. NK1R deletion
suppressed alcohol consumption in mice, and the NK1R
antagonist LY686017 blunted the urge of detoxified alco-
holic patients to consume alcohol (105). The NK1R antag-
onist CJ-11,974 decreases sucrose consumption in rats
(322). NK1R deletion also attenuates the rewarding prop-
erties of opioids (225), and the NK1R antagonist L822429
reduces the acute reinforcing actions of heroin in rats (25).
Thus NK1R antagonists could control several addictive be-
haviors.
D. Gastrointestinal Disorders
Preclinical studies and small-scale trials in IBS patients sup-
port the proposal that antagonists of all three NKRsmay be
useful therapies for IBS and related disorders. Analysis of
two phase II studies of women with diarrhea-predominant
IBS treated with the dual NK1R/NK2R antagonist DNK333
revealed relief of IBS symptoms compared with placebo
(358). A small-scale study of female IBS patients evaluated
the effectiveness of the NK1R antagonist AV608 on anxiety
and visceral pain during painful and nonpainful visceral
stimulation, with functional magnetic resonance imaging to
evaluate brain activity (334). AV608 reduced anxiety and
pain ratings, and suppressed activation of the amygdala,
hippocampus, and anterior cingulate gyrus during visceral
distension. IBS and IBD are associated with decreased bind-
ing of an NK1R PET agonist in the brain, which may reflect
release of endogenous tachykinins and NK1R endocytosis,
with a consequent reduction in binding of a PET ligand
(135). Considered together, these studies support further
exploration of NKR antagonists in IBS.
Although IBD is another potential target for NK1R antag-
onists, NK1R disruption delays healing of the inflamed co-
lon, and antagonists could have the side effect of delayed
resolution of colitis (see sect. IVB). Preclinical studies indi-
cate that NK1R antagonists prevent the formation of fi-
brous adhesions after invasive abdominal surgery (see sect.
IVB), which remains to be examined in clinical trials.
E. Respiratory Disorders
The contributions of tachykinins to neurogenic inflamma-
tion and hyperreactivity of the airways led to the suggestion
that NKR antagonists could be treatments for asthma,
bronchitis, and COPD (see sect. IVC). Although FK888, a
peptidic NK1R antagonist, improved exercise-induced
asthma (133), the small molecule NK1R antagonist
CP99,994 had no protective effect on hypertonic saline-
induced bronchial constriction or cough in patients with
mild asthma (91). Moreover, the dual NK1R/NK2R antag-
onist AVE5883 did not protect asthmatics challenged with
allergen, despite its antagonistic activity against inhaled
NKA (39). A review of clinical trials of NKR antagonists as
a treatment for asthma concluded that while there is a po-
tential of NKR antagonist to decrease airway hyperrespon-
siveness and improve lung function, their effects on airway
inflammation and asthma symptoms have not been studied
in sufficient detail to warrant firm conclusions, suggesting
the need for large-scale trials (274).
F. Urogenital Disorders
Preclinical studies indicate that tachykinins regulate con-
tractility of smooth muscle in the urinary tract, suggesting
that NKR antagonists may be treatments for bladder disor-
ders (see sect. IVD). Overactive bladder, which is defined as
urgency with or without incontinence, is a common disor-
der that severely compromises quality of life, and existing
treatments with anticholinergic drugs have side effects such
as constipation, dry mouth, and dry eyes. A large trial of
patients with overactive bladder revealed that although the
NK1R antagonist serlopitant decreased the daily number of
urination episodes compared with placebo, it was no more
effective than tolterodine (M2/M3 muscarinic receptor an-
tagonist) and, unlike tolterodine, serlopitant did not reduce
urgency or incontinence relative to placebo (100). Whether
theNK2R, which is expressed by bladder detrusormuscle of
all mammalian species studied, is a target for overactive
bladder remains to be clinically evaluated.
G. Sensory Disorders of Pain and Pruritus
Extensive preclinical studies implicate SP and the NK1R in
somatic and visceral pain (see sect. IV, B and F). Although
the NK1R antagonist CP-99,994 reduced postsurgical pain
of patients undergoing tooth extraction compared with pla-
cebo (81), NK1R antagonists were subsequently shown to
be ineffective in other pain states in humans (126).
A novel strategy to develop improved analgesics has been to
generate chimeric molecules composed of an NK1R antag-
onist and an opioid agonist, with the rationale that block-
ade of the algesic NK1R and activation of the analgesic
opioid receptor would be a more effective therapy than
targeting the individual receptors. A bifunctional chimeric
peptide, [Dmt-D-Arg-Aba-Gly-NMe-30,50-(CF3)2-Bn], is a
NK1R antagonist, a balanced agonist of - and -opioid
receptors, and is algesic in mice (20, 116). The usefulness of
such compounds in humans awaits evaluation.
Chronic pruritus accompanies diverse diseases that affect
the skin (atopic dermatitis) and other organs (kidney, liver).
Preclinical studies indicate that NK1R antagonism attenu-
ates scratching behavior in a picrylchloride-induced derma-
titis model in mice (241). A small study of patients with
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untreatable chronic pruritus revealed that the NK1R antag-
onist aprepitant caused a marked reduction of itch intensity
(320). These studies justify a randomized, controlled clini-
cal trial to fully evaluation the effectiveness of NK1R antag-
onists to treat chronic pruritus.
H. Viral and Bacterial Infections and Sepsis
In view of the major role of SP and the NK1R in regulation
of immune functions (see sect. IVG), there has been consid-
erable interest in use of NK1R antagonists to treat viral and
bacterial infections. SP levels are elevated in the circulation
of HIV-infected individuals (83), and SP enhances HIV rep-
lication inmononuclear phagocytes andmacrophages by an
NK1R-mediated mechanism (174). This effect of SP may
depend on NK1R-induced expression of the chemokine re-
ceptor CCR5, a coreceptor for HIV. A small-scale trial of
HIV patients revealed that aprepitant was safe but at the
doses used did not show significant antiviral or immuno-
logic improvement (333). Deletion of Tac1 or antagonism
of the NK1R protects mice from polymicrobial sepsis and
airway inflammation induced by cecal ligation and punc-
ture (122, 268). Thus NK1R antagonist may be effective
therapies for bacterial sepsis, which remains to be studied in
humans.
I. Cancer
Multiple studies suggest that tachykinins induce prolifera-
tion and migration of tumor cells and that NKR blockade
has antiproliferative and proapoptotic actions (see sect.
IVH). Although these studies point to therapeutic utility of
NKR antagonists in cancer, this possibility has yet to eval-
uated in clinical trials.
VI. CONCLUSIONS AND FUTURE
PERSPECTIVES
Tachykinins are one of the most intensively studied families
of neuropeptides. The early realization that tachykinins reg-
ulate important pathophysiological processes, such as in-
flammation, immunity, and nociception, provided the im-
petus for these studies. Knowledge of the structure, func-
tion, and regulation of tachykinins undoubtedly guided
studies of other neuropeptides, confirming the importance
of tachykinins as “pioneering neuropeptides.” The NKRs
are also one of the most studied families of GPCRs. Infor-
mation about the signaling, trafficking, and properties of
NKRs certainly influenced studies of other GPCRs, estab-
lishing their position as “pioneering receptors.” Preclinical
studies implicating involvement of NKRs in diverse disor-
ders, including inflammatory diseases, pain, affective disor-
ders, and vomiting, stimulated the pharmaceutical industry
to develop antagonists of all three NKRs. On one hand,
these efforts were successful: NKR antagonists are selective,
potent, safe, and show good bioavailability. On the other
hand, they were a major disappointment: apart from the
usefulness of NK1R antagonists to treat nausea and vomit-
ing after chemotherapy and surgery, large-scale trials failed
to support further development of antagonists for the treat-
ment of pain, depression, or bladder disorders.
Has the lack of widespread clinical utility dampened inter-
est in tachykinins, and are NKRs still a viable therapeutic
target? Judging from the ongoing reports of involvement of
tachykinins in important physiological processes and dis-
eases, including cancer and infection, the tachykinin field
remains vibrant. There are also multiple ongoing clinical
trials of NKR antagonists, suggesting that interest in indus-
try is sustained. Moreover, recent preclinical studies of the
involvement of tachykinins in fibrosis and pruritus support
clinical studies of NKR antagonists in other disorders.
The reason why NKR antagonists failed in many clinical
trials remains a mystery. Plausible explanations for failure
include the use of inappropriate experimental models for
preclinical development, the inappropriate selection of pa-
tients and end-points for efficacy in clinical trials, and a lack
of understanding of the structural basis of antagonist inter-
action with NKRs. A deeper understanding of the molecu-
lar mechanisms of human disease is required for the devel-
opment of suitable experimental models for evaluation of
effectiveness of therapies, including NKR antagonists. This
knowledge will inform trials of more homogeneous patient
groups and permit the identification of more sensitive and
specific end-points. Knowledge of the three-dimensional
structure of NKRs in combination with agonists, antago-
nists, and signaling partners, including G proteins and -ar-
restins, will facilitate drug design. The next generation of
NKR antagonists could include allosteric modulators,
which would permit finer control of signaling by endoge-
nous tachykinins. Since tachykinins often act in concert
with CGRP, drugs that simultaneously antagonize tachy-
kinin and CGRP receptors may be more effective, and NKR
antagonists in combination with opioid receptor agonists
are already being studied for pain. Finally, the subcellular
targeting of NKR antagonists to disrupt disease-relevant
compartmentalized signaling may lead to increased speci-
ficity and fewer side-effects. Clearly, there is much still to
learn from the study of tachykinins and NKRs.
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